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SUMMARY
Biomineralization of the extracellular matrix is an
essential, regulated process. Inappropriate minerali-
zation of bone and the vasculature has devastating
effects on patient health, yet an integrated under-
standing of the chemical and cell biological pro-
cesses that lead to mineral nucleation remains
elusive. Here, we report that biomineralization of
bone and the vasculature is associatedwith extracel-
lular poly(ADP-ribose) synthesized by poly(ADP-
ribose) polymerases in response to oxidative and/or
DNA damage. We use ultrastructural methods to
show poly(ADP-ribose) can form both calcified
spherical particles, reminiscent of those found in
vascular calcification, and biomimetically calcified
collagen fibrils similar to bone. Importantly, inhibition
of poly(ADP-ribose) biosynthesis in vitro and in vivo
inhibits biomineralization, suggesting a therapeutic
route for the treatment of vascular calcifications. We
conclude that poly(ADP-ribose) plays acentral chem-
ical role in both pathological and physiological extra-
cellular matrix calcification.
INTRODUCTION
Biomineralization is the deposition of mineral particles within a
proteinaceous organic matrix. In bone, this is an essential physi-
ological process (Rey et al., 2009), but extensive pathological
calcification of soft tissues, in particular the vasculature (Abedin
et al., 2004; Johnson et al., 2006; Shao et al., 2006; Demer and
Tintut, 2008; Kapustin and Shanahan, 2009), commonly occurs
in association with disease. Determining how this complex chem-
ical process is controlled is relevant to both bone development
and the treatment of detrimental conditions such as ‘‘hardening
of the arteries.’’ Despite increased understanding of the cell bio-
logical processes involved in biomineralization, the chemical
mechanism of mineral nucleation remains elusive. Any proposed
mechanism must explain the onset of mineralization, the spatial
distribution of the mineral, its particle morphology, and why cal-
cium is the dominant metal ion in the mineral. In turn, these
must be consistent with cellular biomolecular synthesis (Combes
et al., 2016).
In both bone and soft tissues, collagen is the predominant
extracellular matrix (ECM) substrate mineralized, and apatitic
calcium phosphate, with various ionic substitutions (Combes
et al., 2016; You et al., 2017), is the dominant mineral phase.
In both cortical and trabecular bone, mineral platelets are highly
organized around ordered collagen fibrils. In the vasculature,
where calcification occurs at two anatomical sites—the vessel
intima during atherosclerosis and the vessel media in aging,
diabetes, and chronic kidney disease (CKD)—the mineral de-
posits are typically dystrophic, and a range of substrates can
be calcified. These include collagen fibrils, though organized
mineral akin to that in bone is rarely observed; striated elastin
(Shimamura, 1970); and spherical nanostructures (Shimamura,
1970; Bertazzo et al., 2013; Hutcheson et al., 2016) that may
originate from cell-derived extracellular vesicles (EVs) (Rey-
nolds et al., 2004; Kapustin et al., 2015). Despite intensive
study, it remains unclear how calcium ions are selectively and
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locally concentrated over other metal ions around these extra-
cellular structures and why collagen fibrils are preferentially
selected as nucleation sites.
Studies in vitro have shown that the formation of bone-like
ordered mineral deposits around collagen fibrils requires other
factors such as additional or substituting mineral ions or non-
collagenous biomolecules (Nudelman et al., 2010; Wang et al.,
2012, 2014). This implies that there is cellular control of ECM
calcification through the secretion of specific factors, but the
identification of these factors remains elusive. In both bone
and the vasculature, biomineralization is accompanied by oste-
ogenic differentiation of resident osteoblasts and vascular
smooth muscle cells (VSMCs), respectively. Osteogenic differ-
entiation results in increased expression of multifunctional acidic
proteins, including the small integrin-binding ligand, N-linked
glycoprotein (SIBLING) proteins, and speculation has focused
on these ‘‘osteogenic’’ proteins as specialist molecules that
may selectively bind calcium ions and provide specificity of inter-
action with collagen fibrils (Donley and Fitzpatrick, 1998; Bini
et al., 1999; Wada et al., 1999; Iyemere et al., 2006; Jahnen-
Dechent et al., 2008; Liu et al., 2013; Veis and Dorvee, 2013;
Al-Qtaitat, 2014). However, although diverse signaling and inhib-
itory roles have been identified (Bini et al., 1999; Wada et al.,
1999; Abedin et al., 2004; Vattikuti and Towler, 2004), these pro-
teins do not have the calcium concentration capacity to induce
collagen calcification. Hence, no physicochemical structural
role in mineral formation has been conclusively demonstrated
(Proudfoot et al., 2002; Boskey, 1989, 2007; Severson et al.,
1995; Bini et al., 1999; Proudfoot and Shanahan, 2001; Moe
et al., 2002; Veis and Dorvee, 2013).
Previously, using nuclear magnetic resonance (NMR) spec-
troscopy, we discovered that poly(ADP-ribose) (PAR) is abun-
dant in the calcifying growth plate of developing fetal bone,
which led us to hypothesize that PAR may play a role in biomin-
eralization (Chow et al., 2014). PAR is a post-translational
modification moiety composed of sugar phosphates that is pro-
duced by PAR polymerase (PARP) enzymes and adducted to
numerous cellular proteins in a process known as PARylation.
Several characteristics of PAR lend support to its possible
extracellular role in biomineralization: first, the pyrophosphate
groups of PAR are predicted to locally bind calcium ions, poten-
tially to the levels needed for mineral nucleation. Second,
PARP1 and PARP2, the dominant PAR-producing enzymes,
are expressed in response to DNA damage and oxidative stress
(Schreiber et al., 2006; Ba and Garg, 2011; Bai et al., 2015; Bru-
nyanszki et al., 2016), both etiologies associated with vascular
calcification. Third, emerging evidence suggests that osteo-
genic differentiation in calcifying osteoblasts is regulated by
PARP activity induced by hydrogen peroxide release from cells
(Robaszkiewicz et al., 2012). Therefore, we explored whether
PAR could control the physicochemical process of mineral for-
mation in the ECM and provide evidence that PAR biosynthesis,
induced in part by the cellular DNA damage response (DDR), is a
unifying factor in physiological bone and pathological artery
calcification.
RESULTS
PAR Is Deposited at Sites of ECM Calcification in Close
Apposition to Cells Exhibiting DNA Damage
Immunofluorescence (IF) was used to examine the juxtaposition
of PAR, DNA damage, and mineralization in the fetal sheep
growth plate and calcified human arteries. PAR deposition was
observed in the acellular ECM abutting the calcification zone of
bone trabeculae. In contrast, in non-calcified cellular regions
(proliferation and/or hypertrophic pre-calcification zone), PAR
was confined to cell nuclei (Figure 1A). Quantification of nuclear:
non-nuclear PAR (Figures 1A andS1) gave 64%± 3%as non-nu-
clear in the calcified trabeculae as compared with 30% ± 5% in
the non-calcified regions. Nuclei of cells lining the bone trabec-
ulae and in the proliferation and/or hypertrophic regions stained
positive for histone H2AX phosphorylation, gH2AX (Figure 1B), a
marker of DNA damage, consistent with nuclear PAR being syn-
thesized as part of the DDR.
Similar deposition of extranuclear PAR was observed at sites
of calcification in arteries within atherosclerotic plaques and
the media, in contrast to non-calcified areas in diseased or
normal arteries, where PAR was exclusively in cell nuclei. Cells
in close proximity to calcification were positive for gH2AX, and
spillage of chromatin into the ECMwas indicative of cell necrosis
at these sites (Figure 1C). Immunohistochemistry (IH) and quan-
tification of PAR performed on a large series of non-calcified
and calcified arteries, exhibiting either intimal atherosclerotic
calcification (carotid arteries) or medial calcification (aorta),
verified the pattern (Figure S1) of nuclear PAR in non-calcified
vessels and/or areas and abundant extracellular deposition in
areas with mineral. Reflectance mode microscopy demon-
strated that the PAR in calcified aorta was located mostly be-
tween elastic lamellae of the vessel media (Figures 1B, 1D, and
S1). Quantification of the ratio of nuclear versus extracellular
PAR in human arteries showed a clear correlation between extra-
cellular PAR deposition and calcification (Figure 1D).
Figure 1. Extranuclear PAR Correlates with Extracellular Matrix Calcification In Vivo
(A) Confocal images of unmineralized (proliferation zone) and mineralized fetal sheep growth plate taken from the same sample, showing the distribution of PAR
with respect to mineral, with quantification of the fraction of PAR signal that is non-nuclear in a series of images. Graph showsmean ± SD. (See Figures S1A–S1C
for image processing.)
(B) Confocal images from the same sample as in (A) showing the distribution of gH2A.X.
(C) Confocal images of human carotid artery taken from calcified and noncalcified regions of the same vessel, showing the distribution of PAR and gH2A.X.
Images in (A)–(C) are maximum intensity projections of z stacks (see also Figures S1D and S1E).
(D) Immunohistochemistry of young uncalcified and aged calcified human vessels showing mineral and PAR staining. Quantification of extranuclear PAR and
mineral in n = 23 vessels shows a correlation between the extent of extranuclear PAR and calcification in the vessel (see Table S1 for details). Correlation was
performed using a Pearson Test (see also Figure S1F).
All scale bars 50 mm, unless otherwise indicated (i.e., in B).
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PAR Is Deposited in the ECM of VSMCs and Osteoblasts
in Response to Calcification Stimuli
Primary bovine VSMCs (bVSMCs) and MC3T3 E1 osteoblasts
in vitro were used to model how induction of ECM calcification
relates to PAR synthesis, ECM calcification being induced with
b-glycerol phosphate (Mody et al., 2001; Kapustin et al., 2011;
Robaszkiewicz et al., 2012; Addison et al., 2015).
Transmission electron microscopy (TEM) showed that MC3T3
osteoblasts lay down well-structured, highly ordered collagen
fibrils (Figures 2A and S2D), and mineralization occurs exclu-
sively as organized apatitic mineral platelets around these fibrils
(Figures 2A, 2B, and S2A–S2D). Using IF early mineralization is
characterized by diffuse mineral staining in cellular regions with
an abundance of nuclei (yellow arrows in Figure 2B), while at later
stages, there are few cell nuclei and heavily calcified collagen
fibrils (Figures 2B and 2C).
PAR was barely detectable in cells prior to calcification (Fig-
ure 2D) but was strongly detectable in regions of early calcifica-
tion (Figures 2B–2D). Plot profiles of confocal images show PAR
co-localizing with mineral (Figure 2B) and, to a lesser extent, with
nuclear DAPI, and quantification revealed 52% ± 12% of PAR
was nuclear and 48% ± 12% non-nuclear (Figure 2D), as
compared with (98% ± 1%) nuclear PAR in positive controls
where PAR biosynthesis was induced with hydrogen peroxide
(Figure S2E).
Mineral deposits scatter incident laser light in confocal imag-
ing; therefore, to determine whether PAR was also present in
or around heavily calcified collagen fibrils, we used multiphoton
and second harmonic generation (SHG) imaging (Figure 2E). This
showed the expected parallel arrays of collagen fibrils and
considerable fluorescence intensity fromPAR between the calci-
fied collagen fibrils.
Under control conditions, bVSMCs produce well-structured
collagen fibrils and elastin (Figure S2I) with no detectable mineral
patches (‘‘unmineralized’’ in Figure 2I) and essentially no observ-
able PAR. In contrast, under calcifying conditions, no collagen
was visible by TEM, SHG spectroscopy, or NMR spectroscopy
(Figures 2F, S2G, and S2J), and regions containing numerous
ovoid or circular patches of extracellular mineral (Figure 2F and
left-hand side of Figure 2G; enlarged in Figure S2K), typically
1–5 mm in diameter, were observed. Regions adjacent to these
calcified areas typically exhibited both nuclear and non-nuclear
Figure 2. Calcification Correlates with PAR Synthesis In Vitro
(A–E) MC3T3 cell analysis.
(A) Mineral morphology and spatial distribution with respect to collagen fibrils observed by SEM (backscattered) and TEM. See also Figures S2A–S2D.
(B) Confocal image showing calcified collagen fibrils (green) and early-stage calcification area (yellow arrows).
(C) Higher magnification confocal image of an area of early-stage calcification and plot profile. PAR, red; nuclei, blue; calcium, green in (B) and (C).
(D) Color separations of confocal images for unmineralized MC3T3 matrix and the early-stage calcification area in (C) with quantification of extranuclear PAR in
mineralized and positive control (H2O2-treated) samples. Graph showsmean ± SD. See Figure S2E for controls and Figure S2F for details of image quantification.
(E) Multiphoton images of an area of heavy matrix calcification, such as that in (B).
(F–J) VSMC cell analysis.
(F) Mineral morphology from TEM. Scale bar 500 nm. See also Figures S2G–S2J.
(G) Confocal image showing heavily calcified area (left, green) and earlier-stage calcification (right) containing PAR (red). See also Figure S2K.
(H) Plot profiles showing the distribution of PAR (red), nuclei (blue), and calcium (green).
(I) Color separations of confocal images for non-induced VSMC and mineralizing VSMC cultures with quantification of extranuclear PAR in mineralized and
positive control (H2O2-treated) samples. Graph shows mean ± SD. See Figure S2L for controls and Figure S2M for details of image quantification.
(J) Multiphoton images of an area of heavy matrix calcification such as that in (G).
Scale bars 20 mm for (C)–(E), (I), and (J) and 50 mm for (B), (G), and (H).
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PAR (Figures 2G and 2I), mainly in small spherical structures less
than a micron in diameter (Figures 2I and S2K), with some larger
PAR-containing circular regions 2–6 mm in diameter (Figure S2K).
Plot profiles of confocal signal intensities through calcified and
adjacent regions showed (Figure 2H) PAR and calcium co-local-
ization with widespread non-nuclear PAR in calcified regions.
Quantifying the nuclear:non-nuclear PAR in calcified areas
(Figure 2I) gave 78% ± 5% non-nuclear PAR compared to
5% ± 3% non-nuclear PAR in hydrogen peroxide-treated
bVSMCs (Figure S2L).
PAR Binds to the ECM
As PAR is normally considered to be an intracellular moiety, we
were interested to discover whether PAR can bind to the ECM.
The bVSMCs that formed ECM were subjected to cell lysis,
and the extracted ECM (Mody et al., 2001; Peiro´ et al., 2001;
Johnson et al., 2006) was examined using 2D 13C-13C correlation
NMR spectroscopy (Chow et al., 2014) (Figure S3A), which re-
vealed significant quantities of PAR suggesting it can be
‘‘captured’’ by ECM components. The same spectra did not
contain the distinctive deoxyribose C10–C20 correlation signal
from DNA (Figure S3B), suggesting that all nuclear material
had been removed from the ECM (Chow et al., 2014).
To visualize its deposition in the ECM, primary human VSMCs
(hVSMCs) were induced to form a calcified matrix by high Ca2+
and inorganic phosphate concentrations modeling the dysregu-
lated mineral metabolism observed in CKD. After 7 (pre-calcifi-
cation) and 18 days (calcification), the cells were lysed and the
remaining ECM washed extensively. DAPI staining confirmed
the absence of DNA and/or extraneous nuclear material (Fig-
ures 3A and S3C). Fluorescence imaging confirmed that at
day 7, matrix calcification was minimal and was in the form of
a small number of spherical deposits (Figure 3A). At this time,
PAR was deposited in the ECM in a punctate pattern co-local-
izing with the EV marker CD63 (Figure 3D), and the mineral
spheres invariably co-localized with PAR puncta (Figure 3A).
After 18 days, calcified spheres averaging 5 microns in size
were spread throughout the ECM, and PAR deposition was
more extensive (Figures 3A!3C). The punctate pattern of
PAR co-localizing with CD63 remained visible, but in addition,
there was now more extensive deposition in a fibrillar pattern
that co-localized to a large extent with fibronectin (Figure 3D).
Calcified spheres were interspersed on this fibrillar pattern of
PAR staining (Figure 3A). Treatment with the PARP1/2 enzyme
inhibitor PJ34 blocked calcification at day 18 and dramatically
reduced PAR deposition in the ECM, although there was
some residual PAR co-localizing with CD63 (Figure 3A). The
use of a control immunoglobulin G (IgG) confirmed the speci-
ficity of the PAR antibody (Figure S3C). Calculation of the
integrated density of PAR using ImageJ showed a significant
increase at day 18 and its inhibition with PJ34 (Figure 3E).
Protein slot blot analysis confirmed the presence of PAR in
both the ECM and isolated EVs, the increase in ECM PAR
deposition at 18 days, and its inhibition by PJ34 (Figures 3F
and S3D).
To determine what components of the ECM might bind PAR,
we analyzed publicly available databases of known PARylated
proteins and identified fibronectin and annexins as proteins
relevant in calcification and present in the ECM and VSMC-
derived EVs (Shanahan et al., 2011; Kapustin et al., 2015). Using
boronate beads that selectively bind PAR to isolate PARylated
proteins from lysates of ECM and EVs and western blot, we
found that fibronectin and annexin 6 were retained by the
beads. Treatment of the VSMCs with the PARP inhibitor PJ34
reduced bead binding to fibronectin and annexin 6 in ECM
and EV lysates (Figures 3G and S3E). Western blot of the input
lysates showed equal levels of fibronectin and annexin 6, con-
firming PJ34 treatment had no effect on protein synthesis or
secretion (Figure 3G).
PAR Forms Amorphous, Calcium-Rich Spheres with an
Affinity for Collagen Fibril Hole Zones
We next explored the physicochemical properties of PAR to un-
derstand its role in the process of ECM calcification. We hypoth-
esized that PAR acts by collecting calcium ions; thus, the first
step was to determine the calcium-binding affinity of PAR
compared with other biologically relevant divalent metal ions.
Dynamic light scattering (DLS) was used to examine the cal-
cium-binding properties of PAR in aqueous solution (Figure 4A),
and bright-field (BF)-TEM, energy-dispersive X-ray spectros-
copy (EDX), and single-area electron diffraction (SAED) were
used to examine PAR morphology in the presence of calcium
ions (CaCl2) (Figures 4B and 4C).
DLS indicated that the PAR hydrodynamic radius increased
dramatically with calcium chloride addition (Figures 4A and
S4A). TEM images (Figures 4B and 4C) from solutions of PAR
and calcium chloride deposited on grids showed electron-dense
spheres. EDX (Figures 4B and S4) showed that the spheres
contained calcium, as well as phosphorus consistent with PAR
pyrophosphate groups, suggesting the spheres consisted of
PAR-bound calcium ions. SAED revealed no diffraction spots or
rings indicating that thematerial in these sphereswas amorphous
Figure 3. PAR Is Released into the ECM via Cell Lysis and EVs and Binds ECM Proteins
(A) Immunofluorescence showing deposition of PAR and co-localization with OsteoImage in the ECM from hVSMCs treated in calcifying conditions for 7 and
18 days in the presence or absence of PJ34. Scale bar, 25 mm. See also Figures S3A–S3C.
(B) Quantification ofmineralization in the ECMof hVSMCs induced to calcify in the presence or absence of PJ34 (n = 3). Mean ±SD, 2-way ANOVA, ****p < 0.0001.
See also Figures S3D and S3E.
(C) Quantification of calcified particle size (OsteoImage spheres) at day 18 after induction of calcification (n = 3). Mean ± SD.
(D) Immunofluorescence showing deposition of PAR and co-localization with CD63 and fibronectin in the ECM from hVSMCs treated in calcifying conditions for 7
and 18 days in the presence or absence of PJ34.
(E) Quantification of PAR deposition in the ECM in calcifying conditions in the presence and absence of PJ34 (n = 3). Mean ± SD, 2-way ANOVA, ****p < 0.0001.
(F) Protein slot blot showing increased PAR production in calcifying hVSMCs (CaP) and its inhibition by PJ34 (representative of n = 2 experiments).
(G) Boronate bead binding assay and western blot for fibronectin and annexin 6 showing reduced binding to PAR in the ECM of hVSMCs treated with PJ34
(representative of n = 2 experiments). Input shows equal loading onto beads.
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(Figure 4B, right inset). The diameter of the spheres depended on
Ca2+ concentration as assessed from TEM images (Figures 4E
and S4B), and PAR molecular conformation as assessed by cir-
cular dichroism (CD) spectra (Figure 4E) also varied with Ca2+
concentration, suggesting that PAR has a large Ca2+ binding
capacity.
In contrast to the case for Ca2+ ions, PAR showed almost no
affinity for other divalent metal ions (Mg2+ and Zn2+), except for
Figure 4. PAR Has Considerable Ca2+ Bind-
ing Capacity
(A) Hydrodynamic radius of PAR in the presence of
Ca2+ measured by DLS. See also Figure S4A.
(B) EDX and SAED (inset, right) of PAR-Ca spheres
observed by TEM (inset, left). See Figure S4B for
details of analysis.
(C) PAR-Ca spheres increase in diameter with Ca2+
concentration.
(D) Comparison of the morphology of PAR in the
presence of Ca2+ compared with other divalent
metal ions and PAR alone. Scale bars, 100 nm for
(B)–(D). See also Figure S4C.
(E) CD spectra of PAR + Ca2+ as a function of Ca2+
concentration.
(F) PAR-Ca sphere diameter as a function of
Ca2+ concentration. See Figure S4B for details of
analysis.
(G) Bright-field (BF)-TEM of collagen fibrils incu-
bated with PAR in the presence of calcium ions
(0.5 mM CaCl2) showed that calcium-rich PAR
spheres were found almost exclusively bound to
the surface of the collagen fibrils preferentially at
the hole zones (arrows). See Figure S4D for details
of analysis.
Mn2+ (Figures4DandS4C),which alsopro-
duced electron-dense spheres (Figure S4).
However, the radius of the Mn-PAR
spheres did not increase in size when the
Mn2+ concentration was increased from
1 mM to 4.5 mM. This suggests that at
1 mMMn2+, the PAR Mn-binding capacity
is already saturated, and PAR has lower
affinity for Mn2+ than for Ca2+. As a control,
we examined Ca2+ binding properties of
DNA, as a polynucleotide analogous to
PAR (Figure S4C), but TEM imaging
showed no spheroidal structure formation
with Ca2+.
We then used TEM to examine whether
PAR-Ca2+ spheres can interact with
collagen fibrils when introduced to the
PAR/CaCl2 buffered solution. The TEM
images show that PAR-Ca spheres avidly
bound to collagen fibril surfaces (Fig-
ure 4F). The PAR-Ca2+ spheres showed
a significant preference (86% ± 6%; Fig-
ure S4D) for binding to the collagen fibril
hole zones (Figure 4F, arrows), the region
hypothesized to be the site of initial min-
eral nucleation (Glimcher, 1984; Weiner and Traub, 1986; Landis
et al., 1993; Mahamid et al., 2010).
PAR Generates Bone-like Calcification of Collagen
Fibrils
We next asked whether the PAR-Ca2+ spheres could, in the
presence of inorganic phosphate, induce bone-like calcification
of collagen fibrils (Reznikov et al., 2018). Addition of PAR to
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buffered calcium phosphate solution (4.5 mM CaCl2, 2.1 mM
K2HPO4) alone, without collagen fibrils, resulted in formation
of amorphous, calcium-rich, electron-dense spheres (Fig-
ure 5A), highly similar in appearance to those formed with
CaCl2 and PAR, again with diameters dependent on Ca
2+ con-
centration. Of note, the diameters of these PAR-Ca phosphate
spheres were in the range of the spheroidal mineral deposits
found in our in vitro models, which are also described in calci-
fied vascular tissues in vivo (100 nm – few microns) (Shima-
mura, 1970; Bertazzo et al., 2013; Hutcheson et al., 2016). By
SAED (Figure 5A, inset), these PAR-induced spheres were still
amorphous even after incubation for 14 days in calcium-phos-
phate rich buffer, suggesting that they are stable in the absence
of collagen fibrils or other perturbing influence for some consid-
erable period.
The introduction of collagen fibrils to PAR in the same buffered
calcium phosphate solution induced heavy mineralization of the
fibrils after 14 days, with numerous nanoscopic mineral platelets
aligned along the fibrils (Figure 5B, left) in an ordered manner
reminiscent of bone mineral (Shimamura, 1970; McNally et al.,
2012; Nudelman et al., 2012). This ordered platelet alignment
was confirmed by SAED, which showed distinct arcs consistent
with crystals with preferred orientation (Figure 5B). At a higher
magnification, distinct zonation of mineral deposition with
respect to the collagen fibril structure was visible (Figure 5C).
A density plot revealed the distance between mineral density
maxima to be "66 nm, in close agreement with the length of
the D-period of collagen fibrils, suggesting that mineral nucle-
ation and growth depend on the underlying collagen fibril
structure. At intermediate time points, Ca-PAR spheres interact-
ing with partially calcified collagen fibrils were observed (Fig-
ure S5A), suggesting these spheres could be directly involved
in collagen fibril calcification. Consistent with this notion,
Figure 5. PAR Can Induce Calcification of Extracellular Matrix
Components
(A) TEM image of PARwith 4.5 mMCa2+ (CaCl2), 2.1mMPO4
3! (K2HPO4) TRIS
buffered solution showing spheres, similar to the calcium-rich PAR spheres
seen after incubation with CaCl2 alone. Scale bar, 100 nm.
(B) TEM images of the mineral resulting from co-incubation of collagen fibrils in
the presence (left) or absence (right) of PAR in vitro with a buffered solution
containing 4.5 mM Ca2+ and 2.1 mM phosphate for 14 days. Scale bars,
250 nm. See also Figure S5A.
(C) Higher TEM magnification (left) showing the periodicity (arrows) of the
mineral deposition in the PAR-calcified collagen fibrils (unstained). Density
plot (right) taken from the boxed area shows the distance between maxima
was "66 nm.
(D and E) TEM (D) and SEM (E) of resin thin section of elastin + PAR and
elastin alone incubated in Ca2+ and PO4
3! solutions for 14 days. White
arrowheads in TEM images indicate fine, electron-dense material; white
arrows denote larger areas of electron-dense material. G, gelatine; E, elastin.
Secondary electron (SE) SEM images of elastin + PAR samples to assess the
surface topography of elastin after incubation show numerous spheres on
elastin surfaces, and elastin alone does not. Backscattered (BS) images
show electron-dense areas as lighter, and they show the elastin + PAR
sample spheres are electron dense and that the surface of elastin-alone
samples is covered with diffuse, electron-dense material. See Figure S5B for
controls and Figure S5C for more images.
(F) Block-face SEM images of rat medial aorta calcification induced bywarfarin
diet. Yellow arrows indicate areas of electron-dense material.
Scale bars, 500 nm for (D)–(F).
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Figure 6. PARP Inhibitors Decrease Calcification of hVSMCs In Vitro
(A) qRT-PCR analysis of hVSMCs andMC3T3 cells in vitro shows expression of PARP1 and PARP2 enzymes in control cultures. hVSMC cultures under calcifying
conditions show increased expression of PARP2 (n = 3).
(B) Slot blot of hVSMC and MC3T3 cells under calcifying conditions showing increased PAR.
(C) The o-cresolphthalein assay (n = 3) showed a time-dependent increase in mineralization, which was inhibited in a dose-dependent manner by the PARP
inhibitor PJ-34 (0.5, 1.5, and 10 uM).
(legend continued on next page)
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collagen fibrils in buffered calcium phosphate without PAR (Fig-
ure 5B, right) showed calcification more typical of a ‘‘wet precip-
itate,’’ consistent with previous observations (Nudelman et al.,
2010). The mineral crystals that did form in the PAR-free solution
were randomly nucleated along the collagen fibril and not
aligned with the fibril.
We also tested the affinity and calcification potential for PAR-
Ca2+ droplets on elastin (Shimamura, 1970). Elastin was calcified
in vitro in the buffered calcium phosphate solution as before.
When PAR was present, mineral formed on elastin fragments
in irregularly shaped patches (Figure 5D), highly similar to the
mineral morphology found in vitro in bVSMC calcified ECM (Fig-
ures 2F and 2G) and in vivo around elastin fibers at the earliest
stages of mineralization in a rat model of aortic calcification (Fig-
ure 5F) (Price et al., 1998; Gourgas et al., 2018). We also
frequently observed what appeared to be Ca-PAR spheres
bound to elastin surfaces (Figure 5E). In the absence of PAR,
like collagen, the elastin surface was calcified with wet precipi-
tate only (Figures 5C and S5C).
PARP Inhibitors Inhibit ECM Mineralization In Vitro
To examine the biochemistry of PAR synthesis, qRT-PCR was
used to show that hVSMCs and MC3T3 cells in vitro expressed
PARP1 and PARP2 under control conditions and increased
expression under calcification conditions, with VSMCs selec-
tively increasing PARP2 (Figure 6A). Increased PAR synthesis
under calcifying conditions was confirmed by protein slot blot
analysis (Figure 6B).
The non-selective PARP1/2 inhibitor PJ34 reduced PARP ac-
tivity and inhibited calcification in both human and bVSMCs (Fig-
ures 6C, 6D, and S6) (Bostro¨m et al., 1993). Conversely, the PAR
glycohydrolase (PARG) inhibitor 6,9-diamino-2-ethoxyacridine-
DL-lactate (DEA), which acts to inhibit PAR cleavage and break-
down, led to an increase in mineral deposition (Figure 6E).
Next, we carried out PARP1 and PARP2 enzyme activity inhi-
bition assays for a larger number of PARP inhibitors to establish
their PARP1/2 selectivity (Table S2) and tested these in the
in vitro calcification models. This demonstrated that all inhibitors
were able to reduce calcification of hVSMCs and MC3T3 osteo-
blasts (Figure 6F). Of note, minocycline was the most effective
PARP inhibitor for reducing calcification of hVSMCs, and protein
slot blot analysis confirmed that minocycline could reduce PAR
production (Figures 6G and 6H). Minocycline has previously
been demonstrated to inhibit PARP1 (Alano et al., 2006), but its
selectivity was not tested. The enzyme activity assays we per-
formed showed that minocycline (Figure S6C; Table S2) inhibited
PARP2 at much lower concentrations than those that provide
effective PARP1 inhibition, suggesting that minocycline is acting
as a selective PARP2 inhibitor.
A PARP Inhibitor Can Inhibit Biomineralization In Vivo in
a Rat CKD Model
The efficacy of minocycline to reduce VSMC calcification in vitro
led us to test this inhibitor in vivo. Rats fed a high-adenine
and low-protein diet developed CKD, hyperphosphatemia, and
medial vascular calcification (Diwan et al., 2018). Treatment
with doses of minocycline from 5 to 50 mg/kg had no effect on
parameters of renal failure including serum P, Ca, and creatinine
clearance, confirming that any effects on calcification are likely to
be tissue specific (Figure S7). Calciumquantification showed that
the highest minocycline dose of 50 mg/kg significantly inhibited
calcification in the aorta, femoral, and carotid arteries (Figure 7A).
This was consistent with von Kossa staining of aortic sections
showing a significant reduction in the calcified aortic area in the
minocycline-treated group (Figure 7C), with some animals
completely devoid of calcification (Figure 7B, boxes c1!c4).
CKD was associated with the induction of DNA damage (Shana-
han et al., 2011; Liu et al., 2013) (Figures 7B and 7C), shown by a
significant increase in gH2AX staining of VSMCs in the aorta (Fig-
ure 7D); DNA damage likely preceded calcification as it was also
elevated in minocycline-treated CKD non-calcified aorta (Fig-
ure 7E). Minocycline reduced the levels of gH2AX staining (Fig-
ures 7B and 7D) and maintained vascular integrity and VSMC
number when compared with CKD alone (Figures 7B and 7F).
PAR was detectable in VSMC nuclei in control and CKD animals;
however, deposition in the ECM was only visible in the calcified
arteries of CKD rats. PAR ECM deposition was less evident in
rats treated with minocycline, consistent with the reduced cell
death and ECMcalcification observed (Figure 7B, boxes d1!d4).
The high-adenine and low-protein rat model also causes
increased rates of bone turnover (Diwan et al., 2018); therefore,
we examined the effects of minocycline on bone mineralization.
SEM images of cross sections of long limb bone showed a larger
fraction of calcified tissue in the CKD rats compared to controls.
Minocycline-treated CKD rats showed reduced cortical thick-
ness and areas of reduced mineral density, consistent with inhi-
bition of calcification during bone remodeling (Figures 7G and
7H). High-resolution TEM imaging showed that the mineral
deposition around collagen fibrils in control, CKD, and minocy-
cline-treated CKD rats is similar in morphology and extent.
This suggests that CKD does not interfere with the mechanism
by which extracellular mineral is deposited, only the rate of
bone remodeling with PARP inhibition reducing the amount of
mineral deposited.
(D) PARP activity was reduced by PJ34 treatment in a dose-dependent manner (n = 4) in hVSMC cultures. See Figures S6A and S6B for data on bVSMC
model.
(E) The PARG inhibitor DEA (0.1 mM) increased calcification of hVSMCs treated with high Ca/P media quantified by o-cresolphthalein. (n = 6). Mean ± SEM,
Student’s t test, **p < 0.01, ****p < 0.0001.
(F) PARP inhibitors can block calcification of hVSMCs (n = 3) andMC3T3 (n = 6) cells. PJ = PJ-34, Min, minocycline; Ola, Olaparib; Ruc, Rucaparib; Nir, Niraparib;
Vel, Veliparib; all are at 3 mM. See Table S2 for enzyme inhibitor assay details and Figure S6C for details on minocycline as a PARP1/2 inhibitor.
Graphs in (A), (C), (D), and (F) show mean ± SEM. Statistical significance was tested with one-way ANOVA with Dunnett’s post hoc tests. *p between p < 0.05,
**p < 0.01, ****p < 0.0001.
(G) Alizarin Red S staining of mineral in hVSMC cultures in the absence and presence of PARP inhibitors PJ-34 (3 mM) and minocycline (3 mM).
(H) Slot blot showing increased PAR under calcifying conditions and its inhibition by minocycline (3 mM).
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DISCUSSION
In this study, we show that PAR is present in the ECM of both
physiological developing bone and pathological VSMC calcifica-
tion in vitro and in vivo and that inhibitors of PARP enzymatic
activity reduce mineralization. Biologically, PAR synthesis corre-
lated with oxidative stress and DNA damage signaling—key
pathways implicated in both bone and vascular calcification.
PAR export from the cell, via cell death and EVs, is also consis-
tent with initiating events at sites of mineralization, particularly in
the vasculature.
We also show that PAR has the chemical functionality to
concentrate calcium ions selectively over other divalent metal
ions and can biomimetically mineralize both collagen and elastin,
and it has particular avidity for collagen fibrils. Therefore, in bone
where the initial organic matrix consists almost entirely of
collagen fibrils, the presence of PAR ensures that the mineral
forms in a highly organized arrangement on collagen fibrils and
not in the disordered, randommanner that occurs when collagen
fibrils are exposed to calcium and inorganic phosphate alone. In
the vasculature, where there are both degraded collagen fibrils
(Hutcheson et al., 2016) and elastin fibrils and PAR-containing
spheres and/or vesicles in the ECM, PAR can explain the hetero-
geneity in calcification sites. Taken together, these data provide
a unifying mechanism for the initiation of both physiological and
pathological mineralization, both explaining the physicochem-
ical mechanism of matrix calcification and intriguingly suggest-
ing that the DDR plays a key role in controlling ECM calcification.
PAR Chemistry Explains the Affinity and Periodicity of
Collagen Mineralization
In developing zebrafish bones, calcium phosphate is delivered to
the mineralization front as amorphous globules that then miner-
alize the bone collagen matrix, though what drives the formation
of these calcium phosphate-rich globules is not known (Maha-
mid et al., 2010). Others have demonstrated that collagen fibrils
calcify biomimetically in cell-free experiments in the presence of
the polyanion poly(Asp) through a mechanism where the polyan-
ion sequesters calcium and phosphate ions into amorphous
liquid droplets (a polymer-induced liquid precursor [PILP] phase)
(Olszta et al., 2007) and complexes of pre-nucleation calcium
phosphate clusters. Importantly, the diameter of these struc-
tures (70–90 nm) is similar in size to those we find with PAR (Nu-
delman et al., 2010). By analogy, the PAR-Ca2+ spheres we
observed would most likely form through spatial constraint of
Ca2+ ions by interaction with PAR pyrophosphate groups, sus-
taining locally high calcium ion concentrations. In the absence
of collagen or other ECM solid nanostructures, these PAR-
induced PILP droplets could lead to formation of spherical min-
eral particles, consistent with the observation of such particle
morphologies in collagen-depleted regions of vessels and be-
tween collagen fibers (Bertazzo et al., 2013; Hutcheson et al.,
2016). In contrast, where there are collagen fibrils, the droplets
are directed to interact preferentially with fibril hole zones initi-
ating extensive fibril calcification. We speculate that the prefer-
ential calcification of collagen fibrils is due to the high extent of
interaction possible between collagen fibrils and PAR. We do
not yet know the nature of the PAR-collagen interaction at the
molecular level. It may be due to electrostatic interaction be-
tween the negatively charged PAR polyanion with the collagen
positively charged C-terminal, which is located in the collagen
fibril hole zone (Nudelman et al., 2010), or more sequence-spe-
cific interactions between PAR functional groups and those on
collagen fibrils; the stacked Tyr residues of the collagen C-termi-
nal is a potential PAR-binding site (Eustermann et al., 2010).
PAR has also previously been shown to form liquid droplets
with intrinsically disordered proteins (Altmeyer et al., 2015;
Boskey and Villarreal-Ramirez, 2016), and many of the non-
collagenous acidic osteogenic proteins essential for both bone
and vascular calcification are intrinsically disordered. Addition
of a representative acidic osteogenic protein to the poly(Asp)-
collagen calcifying system resulted in more rapid biomimetic
collagen fibril calcification, suggesting the rate of mineralization
was dependent on the osteogenic protein (Nudelman et al.,
2012). We speculate that complexes or the interplay between
PAR and osteogenic proteins serve to control the rate and den-
sity of calcification, and this requires further exploration.
PAR Delivery to the ECMmay beMediated by Cell Death
and Microvesicle Release
We have demonstrated that PAR can bind to the ECM in in vitro
models of VSMC and osteoblast calcification with cell lysis likely
mimicking cell necrosis, suggesting this may be one route for
PAR delivery to the ECM. We also found a spatial correlation
Figure 7. The PARP2 Inhibitor Minocycline Inhibits Biomineralization In Vivo
(A) Quantification of calcium content in rat arteries under control (n = 4), CKD (n = 14), and CKDminocycline-treated rats (n = 14). Calcium is significantly reduced
in the 50 mg/kg treated group. See Figures S7A and S7B for overview and background data for the in vivo experiments.
(B) Immunohistochemistry of rat aorta from control, CKD, and CKD minocycline-treated rats showing mineral (VK), PAR, DNA damage (gH2AX), and VSMCs
(alpha smooth muscle [aSM] actin). Arrows in row b indicate areas of extracellular PAR, and arrows in row c indicate cells positive for gH2AX. Scale bar, 500 mm.
(C) Quantification of the mineralized area of the aorta in control (n = 4), CKD (n = 14), and CKD minocycline-treated (n = 14) rats.
(D) Quantification of gH2AX staining in the rat aorta from control (n = 4), CKD (n = 14), and CKD minocycline-treated rats (n = 14).
(E) Quantification of DNA damage in control (n = 4) and uncalcified arteries from the CKD minocycline-treated group (n = 6).
(F) Quantification of the total number of smooth muscle cells per unit area in the aorta control (n = 4), CKD (n = 14), and CKD minocycline-treated (n = 14) rats.
(G) Electron microscopy assessment of bones from the treated animals. (top) SEM images (scale bars, 500 mm), below expansions of the indicated areas of the
SEM images (scale bars, 100 mm), and (bottom) TEM images showing details of the collagen fibril calcification (scale bars, 500 nm).
(H) Effect of minocycline on bone remodeling. The area fraction (in %) of ‘‘solid bone’’ in the cortical area of the bone cross section is decreased in minocycline-
treated CKD animals.
All data were tested for normality using Shapiro-Wilk test. (A, C, D, F, and H) Mean ±SEM. Statistical significancewas determined by Kurskall-Wallis test followed
by Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001. (E) Mean ± SEM. Statistical significance was determined by unpaired Student’s t test, *p < 0.05. See
Figure S7C for details of the quantification.
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between CD63, a marker of VSMC EVs, and PAR in the ECM,
suggesting PAR could also potentially deposit in the ECM via
exosome or apoptotic body release. Both fibronectin and an-
nexin 6 are well documented to be present in the ECM and
VSMC-derived EVs (Kapustin et al., 2011, 2015). Annexin 6
was previously found to be PARylated or associated with PAR
in oxidatively stressed cells (Jungmichel et al., 2013), and we
confirmed this in VSMCECMand EV lysates. Mechanisms of an-
nexin-mediated mineralization remain controversial, but it is
plausible that PAR binding may be involved in nucleating the
mineral around EVs to generate spherical calcified particles (Shi-
mamura, 1970; Becker et al., 2004; Bertazzo et al., 2013; Hutch-
eson et al., 2016).
PARP Activity Mediated by Oxidative and DNA Damage
Induces the Production of PAR at Sites of Calcification
PARylation of proteins by PARP1/2 is a canonical pathway in the
DDR, activated in particular by oxidative stress (Luo and Kraus,
2012). Consistent with this, we showed that gH2A.X was present
in cells surrounding sites of mineralization in developing bone
and calcified vessels. The notion of the DDR or cell damage
signaling being essential in matrix calcification is further sup-
ported by previous studies. For example, mice deficient in key
DDR signalingmolecules including ataxia telangiectasia mutated
(ATM) and p38 (Wang and Li, 2007) have defects in bone differen-
tiation and mineralization, and similarly, ATM inhibition can block
mineralization of aged VSMCs in vitro (Liu et al., 2013). Previous
observations that PARP inhibition has additional effects in block-
ing cell necrosis and osteogenic differentiation suggests there
may be additional roles for the DDR signaling cascade in miner-
alization (Robaszkiewicz et al., 2012). The notion that PARP
signaling activated during the DDR, in response to either pro-
grammed (in bone) or pathological (in the vasculature) oxidative
stress, can regulate osteoblast and VSMC osteogenic differenti-
ation and cell death, as well as generate a molecule, PAR, that is
essential to the physicochemical process of ECM calcification, is
ingenious (Chen et al., 2015; Li et al., 2009). That the mechanism
uses components that are considered some of the most ancient
biological molecules—ribose phosphate and adenine (as well as
calcium and inorganic phosphate)—suggests that the mecha-
nism itself may also have ancient roots.
Most importantly, our data in vivo using a rat CKD model of
vascular calcification suggest that PARP inhibitors may be
developed as therapeutics for the widespread condition of
vascular calcification, for which there is currently no treatment.
Development of new PARP inhibitors is currently a growth area
in cancer treatment (Alano et al., 2006; Lee et al., 2007; Kim
et al., 2013), and understanding which PARP enzymes are
responsible for bone and vascular calcification would potentially
allow treatment developments for the specific inhibition of
vascular calcification, mitigating any adverse effects on bone
mineralization.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-PAR (clone 10H) Enzo Life Sciences Cat#ALX-804-220; RRID:AB_2272987
Mouse monoclonal anti-PAR (Clone 10H) Lifespan Biosciences Cat#LS-C146823; RRID:AB_11142728
Mouse monoclonal anti-PAR (clone 10H) Abcam Cat#ab14459; RRID:AB_301239
Mouse IgG isotype control Abcam Cat#ab18443; RRID:AB_2736846
Rabbit polyclonal anti-Annexin VI Abcam Cat#ab19416, RRID:AB_444903
Rabbit polyclonal anti-fibronectin Abcam Cat#ab2413; RRID:AB_2262874
Rabbit monoclonal anti-gH2AX (Clone 20E3) Cell Signaling Technology Cat#9718; RRID:AB_2118009
Rabbit polyclonal anti- gH2AX(phosphor S139) Abcam Cat#ab11174; RRID:AB_297813
Rabbit polyclonal anti-CD63 (clone H-193) Santa Cruz Biotechnology Cat#sc-15363; RRID:AB_648179
Rabbit polyclonal anti-aSMA Abcam Cat#ab5694; RRID:AB_2223021
Mouse anti-CD63 BD PharMingen Cat# 556019; RRID:AB_396297
Goat anti-Mouse AlexaFluor 546 Invitrogen Cat#A11003; RRID:AB_141370
Goat anti-Rabbit AlexaFluor 488 Invitrogen Cat#A11010; RRID:AB_143156
Goat anti-mouse IgG-Alexa594 Abcam Cat#ab150120; RRID:AB_2631447
Goat anti-mouse IgG-Alexa488 Abcam Cat#ab150117; RRID:AB_2688012
Donkey anti-rabbit IgG-Alexa 647 Abcam Cat#ab150075; RRID:AB_2752244
Goat anti-mouse IgG-Alexa488 Molecular Probes/Invitrogen Cat#A11001; RRID:AB_2534069
Goat anti-rabbit IgG-Alexa568 Molecular Probes/Invitrogen Cat#A11011; RRID:AB_143157
Goat anti-mouse IgG-15 nm gold BBI solutions Cat#EM.GMHL15; RRID:AB_2715551
IRDye 800CW Donkey anti-Mouse LI-COR Cat#926-32212 RRID:AB_621847
IRDye 800CW Donkey anti-Rabbit LI-COR Cat#926-68073 RRID:AB_10954442
IRDye 680RD Donkey anti-Mouse LI-COR Cat#926-68072 RRID:AB_10953628
IRDye 680RD Donkey anti-Rabbit LI-COR Cat#926-68073 RRID:AB_10954442
Biological Samples
Foetal sheep growth plate Provided by Roger Brookes N/A
Chemicals, Peptides, and Recombinant Proteins
(+)-Sodium L-ascorbate Sigma Aldrich Cat#A4034
Gelatin Sigma Aldrich Cat#G9391
Ethanolamine Sigma Aldrich Cat#E0135
Glutaraldehyde Sigma Aldrich Cat#G6257
m-aminophenylboronic acid agarose Sigma Aldrich Cat#A8312
Ponceau S solution Sigma Aldrich Cat#P7170
Anti-pan-ADP-ribose binding reagent Merck Millipore MABE1016
Hydrogen Peroxide solution Sigma Aldrich Cat#H1009
Normal Goat Serum Vector Laboratories Cat#S-1000
Normal Horse Serum Vector Laboratories Cat#S-2000
Antigen Unmasking Solution; citric acid based Vector Laboratories Cat#H-3300
Active PARP1 Abcam Cat#ab79663
Active PARP2 Abcam Cat#ab198766
EDTA-free PAR BioTechne/Trevigen Custom-made
BlockAid Blocking solution ThermoFisher Cat#B10710
DEA (6,9-diamino-2-ethoxyacridine-DL-lactate) Sigma CAS 6402-23-9
Niraparib LGM Pharma CAS 1038915-60-4
(Continued on next page)
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Rucaparib LGM Pharma CAS 28173-50-2
Veliparib LGM Pharma CAS 912444-00-9
Olaparib LGM Pharma CAS 763113-22-0
PJ34 AdipoGen CAS 344458-15-7
Minocycline Cycle Pharmaceuticals CAS 10118-90-8
Calcium Chloride Dihydrate Sigma C27902
Sodium Phosphate monobasic Sigma S-5011
O-cresolphthalein Sigma P5631
Ammonium Hydroxide Solution Sigma 338818
Critical Commercial Assays
OsteoImage Mineralization Assay Lonza Cat#PA-1503
Vectastain Elite ABC HRP kit (peroxidase, Mouse IgG) Vector Laboratories Cat#PK-6102
Vectastain Elite ABC HRP kit (peroxidase, Rabbit IgG) Vector Laboratories Cat#PK-6101
DAB peroxidase substrate kit Vector Laboratories Cat#SK-4100
PARP1 enzyme activity assay Merck Millipore Cat#17-10149
RNeasy mini kit QIAGEN LTD Cat#74104
RT2 First Strand Kit QIAGEN LTD Cat#330404
QuantiFast SYBR Green PCR Kit QIAGEN LTD Cat#204054
HT colorimetric PARP/apoptosis assay kit Trevigen Cat#4684-096-K
DC Protein Assay Kit Bio-Rad Laboratories Cat#5000116
Experimental Models: Cell Lines
MC3T3-E1 murine calvarial osteoblasts (subclone 14) ATCC Cat# CRL-2594
Bovine VSMC obtained from aortic segments
from an abattoir
N/A
Primary human VSMC isolates Explant cultures from aorta. N/A
Oligonucleotides
Osterix (Osx): QT00293181 1 Mm_Sp7_1_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT00293181
Type 1 collagen alpha chain: QT00162204
1 Mm_Col1a1_1_SG QuantiTect Primer Assay
QIAGEN LTD Cat#QT00162204
Osteopontin: QT00157724 1 Mm_Spp1_1_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT00157724
Osteocalcin: QT00259406 1 Mm_Bglap_1_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT00259406
Osteonectin: QT00161721 1 Mm_Sparc_1_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT00161721
PARP2: QT00162281 1 Mm_Parp2_1_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT00162281
PARP1: QT00157584 1 Mm_Parp1_1_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT00157584
GAPDH: QT01658692 1 Mm_Gapdh_3_SG
QuantiTect Primer Assay
QIAGEN LTD Cat#QT01658692
Alkaline phosphatase: QT00157717 1
Mm_Alpl_1_SG QuantiTect Primer Assay
QIAGEN LTD Cat#QT00157717
RT2 qPCR Primer Assay for Human PARP2 QIAGEN LTD Cat#PPH02684F
RT2 qPCR Primer Assay for Human PARP1 QIAGEN LTD Cat#PPH00686B
Hs_BMP2_1_SG QuantiTect Primer Assay QIAGEN LTD Cat#QT00012544
OCN F:GGCAGCGAGGTAGTGAAGAG Integrated DNA Technologies N/A
OCN R: CGATAGGCCTCCTGAAAGC Integrated DNA Technologies N/A
MSX2: F: AAATTCAGAAGATGGAGCGGCGTG Integrated DNA Technologies N/A
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Melinda
Duer (mjd13@cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human vessels samples
Normal vessels and atherosclerotic plaques (aorta and carotid) were obtained from transplant donors and patients undergoing
carotid endarterectomy respectively, with informed consent and approval from the Cambridge Local Research Ethics Committee
LREC 97/084. Age and gender of patients are reported in Table S1. All human materials were handled in compliance with the Human
Tissue Act (2004, UK).
Fetal sheep bone and osteoblasts
Growth plate
Foetal sheep bones (humerus and femur) were dissected out immediately after the sacrifice of the sheep one week before the fetus
would be full-term. The bones were put in a plastic bag and transported to the lab on wet ice. The head of each bone was cut
longitudinally using a microtome knife. The bones were cleaved again horizontally into two smaller pieces. The smaller pieces
were placed in white plastic embedding pots on TissueTek OCT compound and were then covered with OCT The plastic containers
were placed on dry ice for about 15-20 min for the OCT to solidify. Then the samples were wrapped up tightly in tin foil and cooled
to !20#C. Cryosections were cut between 8 and 18 mm thick.
Isolation of osteoblasts
Fetal sheep osteoblasts were isolated from a fetus removed from an 18 weeks pregnant sheep sacrificed for an unrelated study.
Femurs were removed from the fetus. After washing several times with 1% trigene (Medichem International), the femur was stripped
of muscle and non-osseous tissue to expose the bone which was sectioned into small longitudinal pieces and washed with 70%
ethanol followed by repeated washings with Minimum Essential Medium (MEM; Invitrogen) to remove all traces of ethanol. Bone
strips were then transferred to Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) containing bacterial collagenase A
(0.5 mg/mL) and dispase II (3 mg/mL) both from Roche Diagnostics. A total of 100 mL of enzyme-media mixture was used for
bone sections taken from 3 limbs. Bone strips were incubated at 37#C in a shaking water bath for 3 hours to release osteoblasts
into the medium. After incubation the cell suspension was transferred to a fresh tube and the bone sections were rinsed in DMEM
with 20% fetal calf serum (FCS; Invitrogen) to stop the enzymatic digestion. Rinse medium and cell suspension were pooled and
passed through a 40 mm mesh filter (Appleton Woods). The cell suspension was then centrifuged at 1000 g for 5 min at room tem-
perature to pellet the cells. The pellet was re-suspended in DMEM complete medium and transferred to two T-175 cm3 culture flasks
(Nunc) and placed in a 37#C CO2 incubator. When the cultures were almost confluent, cells were detached with 10 mL of 0.25%
trypsin containing 1 mM EDTA (SigmaAldrich) and incubatied for 5 min at room temperature. The flasks were tapped at the end
of incubation period to completely dislodge the cells from the flask. Trypsin was neutralized by adding 15 mL of DMEM complete
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
MSX2: R: CGGCTTCCGATTGGTCTTGTGTTT Integrated DNA Technologies N/A
SMA: F:TTGAAGGCAAAGACATGGCAGCAG Integrated DNA Technologies N/A
SMA: R:TCCACGGTAGTGCCCATCATTCTT Integrated DNA Technologies N/A
SM22: F:TTGAAGGCAAAGACATGGCAGCAG Integrated DNA Technologies N/A
SM22: R:TCCACGGTAGTGCCCATCATTCTT Integrated DNA Technologies N/A
Software and Algorithms
ImageJ NIH https://imagej.nih.gov/ij/download.html
GraphPad Prism GraphPad Software https://www.graphpad.com
Leica Application Suite Leica http://www.leica-microsystems.com/
products/microscope-software/
Bio-Rad CFX Maestro (Real-time PCR analysis) Bio-Rad N/A
Other
Bio-Dot SF Microfiltration Apparatus Bio-Rad #1706542
Casein diet / 3.0 mg/g of warfarin and 1.5 mg/g of vitamin K1 AB diets Code 4165.00
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media to the culture flask. The cell suspension was centrifuged in a 50 mL tube (Greiner) at 1200 rpm for 5 min and resuspended in
10 mL of DMEM. The cells were transferred into T-175 cm3 culture flasks and were expanded to passage 3 for subsequent
experiments.
Basal Medium Eagle (BME) complete mediumwas prepared by adding 10%FCS, 30 mg/mL L-ascorbic acid 2-phosphate (Sigma),
10mL/L L-glutamine-penicillin- streptomycin (200 mM L-glutamine, 10,000 units/ml penicillin, and 10 mg/ml streptomycin in 0.9%
sodium chloride; Sigma). DMEM complete medium was prepared by adding 10% FCS, 30 mg/mL L-ascorbic acid 2-phosphate,
and 10mL/L L-glutamine-penicillin-streptomycin. All supplements were filter sterilized (0.22 mm filter, Appleton Woods) before
addition.
In vitro MC3T3 osteoblast cell line model
MC3T3-E1murine calvarial osteoblasts (subclone 14) were purchased from ATCC (gender unknown). MC3T3- E1 cells were cultured
in a-MEM (Life Technologies) growth medium supplemented with 10% FBS (Life Technologies), L-Glutamine–Penicillin–Strepto-
mycin solution (200 mM L-glutamine, 10,000 U penicillin and 10mg steptomycin/ml, Sigma), at humidified 37#C, 5% CO2 incubator.
Cell differentiation and matrix mineralization were initiated when the cell density reached approximately 80% confluence with miner-
alization medium. Mineralization medium is growth medium supplemented with 50 mg/ml ascorbic acid, 4 mM b-glycerophosphate
(Sigma) and 10nM dexamethasone (Sigma). The medium was changed every three days.
For calcium estimation assays and qRT-PCR experiments, MC3T3 E1 cells were seeded in 24-well plates for each time points.
1 3 104 cells were plated per well and were grouped into three sets each for control, mineralized and mineralized with PJ34. The
control group were cultured in a-MEM growth media, mineralized group in mineralizing media and mineralized with PARP inhibitor
group in mineralizing media with PARP inhibitor PJ34 (5 mM in DMSO). The control group for the PARP inhibitor studies additionally
had 5 mL DMSO added per well.
In vitro human vascular smooth muscle cell (hVSMC) model of calcification
Primary human VSMCs were obtained from a medial aortic explant from a healthy 35 year old female transplant donor with approval
from the Cambridge Local Research Ethics Committee LREC 97/084. The cells were cultured in M199 media (Sigma-Aldrich) sup-
plemented with 20% fetal bovine serum (FBS) and 100 U/ml penicillin, 100U/ml streptomycin and 0.29 mg/ml glutamine (1% PSG),
and incubated at 37#C with 5% CO2.
To induce mineralization, human VSMCs were seeded and then cultured for 1 day in M199 media supplemented with 5% FBS and
1% PSG. Then the cells were incubated in high Ca/P media (M199 media supplemented with 5% FBS and 1% PSG, with a final
concentration of 2.7 mM Ca2+ and 2.5 mM phosphate) or with control media M199 with no additional Ca2+ or P (M199 media sup-
plemented with 5%FBS and 1%PSG, with a final concentration of 1.8mMCa2+/1.0mMP). Themedia was refreshed every 2-3 days.
In vitro bovine VSMC (bVSMC) in vitro model of calcification
bVSMCs were obtained from aortic segments from an abattoir. bVSMC cells were seeded on sterile 8-well chamber slide at a cell
density of 1x104 cells per well in DMEM (Life Technologies) growth medium supplemented with 10% FBS (Life Technologies) and
L-Glutamine–Penicillin–Streptomycin solution (200 mM L-glutamine, 10,000 U penicillin and 10mg steptomycin/ml, Sigma), at
humidified 37#C, 5% CO2 incubator. After three days, growth medium was replaced by mineralization medium (growth
medium+4mM b-glycerophosphate, 50 mg/ml ascorbic acid + 10nM dexamethasone) and was changed every three days till day
twenty when the mineralized nodules are wide spread in culture.
Warfarin-induced vascular calcification in rats
All procedures were performed in accordance with licenses and guidelines approved by the UKHomeOffice andwere approved by a
King’s College ethics committee. Sprague Dawley rats (n = 6; male; 21-27 days old) were purchased fromCharles River Laboratories.
After an acclimatisation period of 7 days, the rats were fed with a custom made rodent diet containing 3.0 mg/g of warfarin and
1.5 mg/g of vitamin K1 (AB diets, Netherlands) After 7 days on warfarin diet, the rats were euthanised and aortas harvested for TEM.
Rat CKD Model
Experimental procedures were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory
Animals 85-23 (1996) and approved by the University of Antwerp Ethics Committee (ethical approval reference number: 2018-19).
Seven-week old male Wistar Han rats (225-250 g, Charles River, Lille, France) (RRID: RGD_2308816) were housed two per cage
andmaintained in a controlled environment with a 12:12 light-dark cycle, room temperature of 22#C and free access to tap water and
their allotted diet. A number of 84 rats were randomly assigned to the following 5 study groups: (i) rats with normal renal function
treated with vehicle (i.e., tap water) (NRF + vehicle) (n = 4); (ii) CKD rats daily treated with vehicle (i.e., tap water) for 6 weeks
(CKD + vehicle 6wks) (n = 14); (iii) CKD rats daily treated with 5 mg/kg minocycline for 6 weeks (CKD + MC/05 6wks) (n = 14); (iv)
CKD rats daily treated with 10 mg/kg minocycline for 6 weeks (CKD + MC/10 6wks) (n = 14); (v) CKD rats daily treated with
50 mg/kg minocycline for 6 weeks (CKD + MC/50 6wks) (n = 14).
Upon arrival in the animal facility all groups were conditioned to a high phosphorus diet (1.03% P and 1.06% Ca) (SSNIFF Special-
dia¨ten, Soest, Germany) for 2 weeks after which CKD and vascular calcification was induced in all study groups by feeding the
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animals a diet containing 0.75% adenine (Acros Organics, Geel, Belgium) (with a 0.92%P and 1.0%Ca content in combination with a
low protein content (2.5% instead of 19.0%)) (SSNIFF Specialdia¨ten) for 4 weeks followed by the high phosphorus diet (1.03% P and
1.06% Ca) until the end of the study. Control animals with normal renal function were fed a standard rodent maintenance diet (0.7%
P and 1.0% Ca) (SSNIFF Specialdia¨ten) for the entire study period.
PARP inhibitor treatment
Minocycline treatment was initiated one week after the start of adenine dosing at three different doses (5, 10 or 50 mg/kg/day).
Minocycline was dissolved in tap water and a constant dose volume of 10 ml/kg was used. Tap water was used as vehicle in the
respective groups. As the half-life of minocycline in the rat is about 3 to 3.5 hours, minocycline was dosed twice a day half of the
indicated dose by gavage with a time interval of 7 hours (Monday till Friday). During the weekends, rats were gavaged the indicated
dose once a day. Animals were subjected to daily treatment for 6 weeks (week 1 until 7) or 4 weeks (week 1 until 5).
At the end of the study, all animals were sacrificed by exsanguination through the retro-orbital plexus after anesthesia with
60 mg/kg ketamine (Pfizer, Puurs, Belgium) and 7.5 mg/kg xylazine (Bayer SA NV, Diegem, Belgium) via intraperitoneal injection.
At baseline (week 0), before start of treatment (week 1), after 3 (week 4), 4 (week 5) and 6 (week 7) weeks of treatment, animals were
individually housed in a metabolic cage for 24 hours to collect urine samples followed by blood sampling. The urinary volume was
recorded and samples were used formeasurement of creatinine. Bloodwas drawn from the tail vein in restrained, conscious animals.
Blood samples were allowed to clot on ice and centrifuged at high speed. The harvested serum was used to determine creatinine,
calcium and phosphorus. To follow renal function serum and urinary creatinine were measured according to the Jaffe´ method.
Creatinine clearance (ml/min) was calculated by the following formula: (urinary creatinine concentration (mg/dl) x urinary volume
(ml)) / (serumcreatinine concentration (mg/dl) x 1440minutes). Total serumphosphorus levels were analyzedwith the Ecoline S Phos-
phate kit (Diasys, Holzheim, Germany) and serum calcium levels were determined with flame atomic absorption spectrometry (FAAS)
(Perkin-Elmer Model AAnalyst 800, Wellesley, MA, USA) after appropriate dilution in 0.1% La(NO3)3 to eliminate chemical
interference.
METHOD DETAILS
Ex vivo sample imaging (Figures 1 and S1)
Ex vivo fetal sheep growth plate mineral, PAR and gH2A.X imaging
Frozen sections of fetal sheep growth plate were thawed for 10 min, soaked for 5 min in PBS to remove OCT and fixed in 100% cold
methanol (!20#C) for 10 min. Then, the sections were permeabilized at RT for 15 min with 0.2% TX100/PBS, then blocked for 30 min
with 3% BSA/0.2% TX100/PBS.
Then, sections were incubated with the primary antibodies (mouse-anti-PAR clone 10H, 1:300 in blocking solution, 600 ml/slide,
LSBio, rabbit-anti-H2A.X, 1:400 in blocking buffer (600 ml/slide), New England Biolabs) at RT for 1h. After rinsing 2x, then washing
3-4x for 5 minutes each in 0.2% Tween 20/TBS, sections were incubated with the secondary antibodies for 45 min at RT (goat-
anti-mouse IgG-Alexa488, 1:300 in blocking solution, 500 ml/slide, Molecular Probes; goat-anti—rabbitIgG (H+L)-Alexa568, 1:300
in blocking buffer, Invitrogen). After washing the slides 3x for 5 min each in 0.2% Tween 20/TBS and twice in PBS, cell nuclei
were stained using Hoechst dye (10 min at RT, 5 mg/ml Hoechst in PBS). After rinsing twice in PBS, slides were covered with
coverslips using ProLong Antifade (Molecular Probes). Sections were viewed in a Leica SP2 confocal laser fluorescence microscope
using the 405 nm, 488 nm and 561 nm laser lines to excite Hoechst, Alexa488 (PAR) and Alexa568 (gH2A.X) dyes, respectively.
Mineral was visible in phase-contrast mode as dark deposits/structures.
Ex vivo vascular sample mineral, PAR and gH2A.X imaging
Low resolution imaging. Human aortic and carotid samples were dissected and fixed into 10% neutral buffered formalin. These sam-
ples were then embedded in paraffin wax blocks and cut in 7 mm thick sections. Immunohistochemistry staining for PAR expression
was performed using human aortic (n = 13) and carotid (n = 10) samples from normal and diseased patients. Parallel sections of the
same samples were processed for von Kossa staining to visualize calcification and counterstained with 0.1% of nuclear fast red so-
lution. The%of calcified area wasmeasured by the threshold method using ImageJ software. For the co-localization of PAR, mineral
and elastin in medial calcification by fluorescence microscopy the same histological sections were used. Elastin was visualized by its
autofluorescence (405 nm laser line), mineral was imaged in reflectance mode (488 nm laser line) and PAR was visualized in trans-
mittedmode. Samples were viewed in a Leica SP2 laser confocal microscope using using a 63x/NA 0.9water-immersion objective. In
all experiments, images were acquired in sequential mode.
High resolution imaging. Frozen sections of human carotid and coronary artery lesions were thawed, rehydrated for 5 min in 0.9%
saline and then fixed for 10 min in 100% methanol cooled to !20#C. Residual methanol was removed by rinsing 2x in PBS. All
following staining steps were performed at RT. In the calcein experiment, lesion mineral deposits were stained with the Ca2+-binding
dye calcein (4 mM in PBS, Sigma C-0875) for 1h; Hoechst 33258 (Sigma B-2883, at 10 mg/ml) was included in the staining solution to
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counter-stain nuclei. Unbound dyes were removed by washing 3x for 5 min each in PBS and sections were thenmounted in ProLong
Antifade Gold (Invitrogen).
For the double immunostaining of PAR and the DNA damage marker gH2A.X, sections were fixed with cold methanol (as above)
and subsequently permeabilized with 0.2% Triton X-100/ PBS for 15 min. After blocking non-specific binding sites with blocking
buffer (3% BSA/ 0.2% TX100/PBS) for 30 min, sections were incubated with primary antibodies (mouse-anti-PAR antibody, clone
10H, Abcam, 1:300 in blocking buffer and rabbit-anti-H2A.X antibody, 20E3, New England Biolabs, 1:400 in blocking buffer) for
1h. After washing sections 4x for 5 min each in washing buffer (0.2% TX100/PBS), sections were incubated with secondary
antibodies (goat-anti-mouseIgG-Alexa488 and goat-anti-rabbitIgG-Alexa568, Invitrogen, both at 1:300 in blocking buffer) for
45 min. Unbound antibodies were removed by washing 3x for 5 min each in washing buffer and 2x in PBS, then nuclei were
counter-stained with 10 mg/ml Hoechst for 10 min. Sections were rinsed 2x with PBS and then mounted as above. Samples were
viewed using a Leica SP2 confocal fluorescence microscope.
In the calcein experiment, lesion mineral deposition was visualized in both transmission and fluorescence mode. Calcein and
Hoechst were excited using the 488 nm and 405 nm laser lines respectively and images were acquired using a 20x/NA 0.5 water-im-
mersion objective. In the double immunostaining experiment, images were acquired using a 63x/NA 1.2 water-immersion objective.
The 405 nm, 488 nm and 561 nm laser lines were used to excite Hoechst, Alexa488 (PAR) and Alexa568 (H2A.X) dyes, respectively.
In vitro cell model imaging and NMR spectroscopy (Figures 2 and S2)
All in vitro experiments using cultured VSMCs or MC3T3 –E1 cells were performed with 3-5 experimental replicates. At least 3 inde-
pendent experiments were performed for each procedure.
Imaging of MC3T3 and bVSMC cell cultures
Confocal Imaging was performed on Leica TCS SP8 confocal microscope (Leica Microsystems). To avoid in-between channel
crosstalk all images were taken in frame sequential mode. Schedule for the dyes was as follows: DAPI excitation 405/ emission
410-540 nm, calcein ex496/em500-520 nm and Alexa-594 ex594/ em600-700 nm. Multiphoton imaging was performed on LaVision
BioTec TriM Scope II (LaVision BioTec GmbH, Germany) equipped with the Inside Deepsee laser light source (Spectra Physics, CA,
USA). Excitation of 1140 nm allowed tri-photon excitation of DAPI (emission collected below 495 nm), generation of second harmonic
(SHG) of collagen (collected 495-560 nm) and two-photon excitation of Alexa-594 (collected above 560 nm).
The fraction of PAR staining which was non-nuclear, was assessed by thresholding the images of PAR and DAPI staining in ImageJ
and calculating the fraction of PAR-positive pixels that did not overlap with DAPI-positive pixels.
PAR detection in MC3T3 and bVSMC cultures
MC3T3-E1 cells were seeded on sterile 8-well chamber slide (LabTech) at a cell density of 1x104 cells per well in a-MEM (Life Tech-
nologies) growth medium. After three days, growth medium was replaced by mineralization medium and was changed every three
days till day thirty when the mineralized nodules are wide spread in culture. bVSMC culture mineralized at day twenty.
The mineralized cultures were washed with PBS and then Calcein AM (1 mM) in PBS was added to the cultures and incubated for
25minutes in humidified incubator. PBSwas added to negative controls instead of calcein. After incubation the cultures werewashed
three time with PBS. For positive controls the cultures were treated with 2mM H2O2 in PBS for 5 min. The cultures were washed in
PBS and fixed with !20#C methanol for 10 minutes. Then cells were washed three times with PBS and permeabilized with 0.4%
Tween 20 in PBS for 15 min at room temperature. The cells were washed twice in PBS and blocked with BlockAid blocking solution
(Thermo) for 30 minutes at room temperature. After blocking, cells were incubated with primary antibody, mouse monoclonal anti-
PAR (clone 10H) antibody (Abcam) / 300 ml/well) diluted (1:300) for overnight at 4#C. Then, cells were washed three times with 0.2%
Tween 20 in PBS and fluorescent dye-labeled secondary antibody (goat-anti mouse IgG (H+L)-Alexa594 antibody (Abcam), (1:500
diluted)) in BlockAid was applied for 1 hour at room temperature. The cells were washed three times in 0.2% Tween20 in PBS then
cells were rinsed twice in PBS. Afterward, PBSwas removed glass coverslips were carefully mounted in Fluoroshieldmountingmedia
with DAPI (4’,6-diamidino-2-phenylindole, Abcam).
Solid-state NMR of MC3T3 and bVSMC calcified matrix
A Bruker 400MHz Avance spectroscopy II spectrometer was used for solid-state 13C (REDOR) and 31P NMR measurements, at
frequencies of 100.6MHz and 162.1MHz respectively, with standard Bruker double (for 31P) and triple (for 13{31P} REDOR) resonance,
magic-angle spinning (MAS) probes. Samples were packed into disposable high-resolution (HR)-MAS inserts, and loaded into 4 mm
zirconia rotors. The rotors were rotated at magic angle at a rate of 10 kHz. Samples were characterized using direct-polarization (DP)
31P NMR and 13C{31P} rotational-echo double resonance (REDOR) techniques (1H 90# pulse length 2.5 ms, 31P 90# pulse length
2.57 ms, 1H-31P CP contact time10ms). Recycle times of 600 s were used for 31P DP experiments, and 2 s for REDOR experiments.
REDOR experiments used REDOR dephasing times of 10 ms. Broadband TPPM decoupling during signal acquisition for all exper-
iments.) 13C spectra were referenced to the glycine Ca signal at 43.1 ppm relative to TMS at 0 ppm.
31P spectra were referenced to the
hydroxyapatite 31P signal at 2.8 ppm relative to 85 wt% H3PO4 at 0 ppm.
Extracellular matrix synthesis for PAR binding assessment (Figures 3 and S3)
Extracellular matrix (ECM) was synthesized by growing hVSMCs to confluency on gelatin coated plates and coverslips. The cells
were then extracted and the ECM used for western blotting or immunofluorescent staining.
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6-well plates and coverslips were prepared by incubating with 0.2% gelatin solution in PBS at 37#C for 1 hour. The solution was
removed and the gelatin was crosslinked by adding 1% glutaraldehyde in PBS and incubating at room temperature for 30 minutes.
The wells and coverslips were washed with PBS and the non-crosslinked glutaraldehyde was quenched by incubating with 1 mol/l
ethanolamine for 30 minutes. Cells were seeded onto the plates (50000 cells for a 6-well plate and 20000 cells for a coverslip) and
after 24 hours the media was changed to complete media supplemented with 50 mg/ml l-ascorbic acid. The media was changed
every 48 hours and after 7 or 18 days the cells were extracted from the ECM.
Extraction buffer (0.1% Triton X-100, 20 mmol/l NH4OH in PBS) was added to the cells and incubated for 5 minutes at 37#C. The
lysed cells were removed and PBSwas added to the ECMovernight at 4#C to remove remaining cell debris. The ECMwas rinsedwith
PBS and either fixed with 3.7% PFA for immunofluorescent staining or scraped in lysis buffer (0.1% Triton X-100, 150mM NaCl in
0.1M Tris-HCl) for IP and slot blot analysis.
Immunofluorescent staining
Immunofluorescent staining of the ECMwas performed to visualize the localization of PAR. Localization was studied by counterstain-
ing with fibronectin (FN), a late endosomal marker (CD63) and calcification (Osteoimage).
Following fixing with 3.7% PFA, blocking was done for 1 hour at RT with 3% BSA (in PBS). The primary antibodies were diluted in
blocking solution and incubated with the coverslips for 1 hour at RT. After washing, the secondary antibody, diluted in blocking
solution, was added and incubated for 1 hour at RT in the dark. 4’,6-diamidino-2-phenylindole (DAPI) was diluted in PBS and
incubated with the coverslips for 5 minutes, to stain nuclei. Following washing, coverslips were mounted with Mowiol mounting
medium and left to dry in the dark at RT overnight. Slides were then stored at 4#C. Imageswere taken using a Leica TCS SP5 confocal
microscope. Quantification was performed on n > 3 images per condition.
PAR area/integrated density was analyzed using ImageJ. The images were converted to RGB stacks andmeasured using the auto
thresholdmethod. The default thresholdmethodwas selected, and percentage area and integrated density weremeasured. The per-
centage area is calculated by dividing the number of pixels that have been highlighted by the threshold by the total number of pixels.
The integrated density is the product of the area and mean gray value (the sum of the gray values of the pixels highlighted by the
threshold, divided by the total number of pixels).
Slot-blot analysis of PAR and PARylated proteins
Cell, ECM, apoptotic body or vesicle lysates were harvested and diluted in TBS. Samples were applied to a Bio-Dot SFMicrofiltration
Apparatus (Bio-Rad) and blotted onto PVDF membrane that had been pre-soaked in TBS using a Welch Vacuum system (Model
2515) at 5 inHg pressure. Membranes were washed in TBS and then stained with Ponceau S solution and imaged prior to blocking
with 5%milk in TBST for and immunodetection of PAR using either 10H anti-PAR antibody or Anti-pan-ADP-ribose binding reagent.
Boronate-IP of PARylated proteins
Lysates weremixed with m-aminophenylboronic acid agarose for 1 hour at room temperature. Following this incubation, beads were
washed twice in SDS wash buffer (1% SDS, 100mM HEPES (pH 8.5), 150mM NaCl) and twice in non-SDS wash buffer (100mM
HEPES (pH 8.5), 150mMNaCl). Proteins were eluted from beads by boiling in 1 x sample buffer for 10 minutes and analyzed by west-
ern blot.
In vitro VSMC extracellular matrix with 13C, 15N-labeling (Figure S3A)
Bovine VSMCs were cultured in a T-175 flask containing 25 mL complete Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen)
with addition of 10% fetal calf serum (First Link), 30 mg/ml L-ascorbic acid 2-phosphate (Sigma) and 10 ml/l L-glutamine-peni-
cillin-streptomycin (200 mM L-glutamine, 10,000 units/ml penicillin, and 10 mg/ml streptomycin in 0.9% sodium chloride; Sigma).
All supplements were filter sterilized (0.22 mm filter, Appleton Woods) before addition. After cells were confluent, labeled (U-13C,
15N) glycine (Cambridge Isotope Laboratories), (U-13C, 15N) lysine (Cambridge Isotope Laboratories) and (U-13C) glucose (Cambridge
Isotope Laboratories) were added after filter sterilization (0.22 mm) to a final concentration of 60 mg/L, 292 mg/L and 4.5 g/L respec-
tively in the complete medium. The culture was incubated at 37#C in a humidified atmosphere of 95% air and 5% CO2. The culture
medium with isotope-labeled supplements was renewed every 2 days.
When cells produced a dense matrix which started to peel off the surface of the tissue culture flask, the medium was removed and
the cells were washed twice with 10 mL phosphate buffered saline (1x PBS, Invitrogen).
Recovery of extracellular matrix
Flasks containing matrix plus cells were placed in a freezer at !80#C for 24 hours and the cells were lysed by thawing the flasks at
room temperature for 30 minutes. The debris produced by cell lysis was removed by repeated washes with PBS. The decellularized
ECMwas dislodged by gently swirling the flask in the presence of 20 mL PBS. The matrix collected in PBS was transferred to a fresh
50 mL centrifuge tube. The ECM was lyophilized overnight. Any adventitious DNA, RNA and PAR was removed by daily incubation
with 40 mM aqueous MgCl2 followed by thorough washing, for two days. The samples were stored at !20#C until NMR analysis.
In vitro fetal sheep osteoblast extracellular matrix with 13C, 15N-labeling (Figure S3B)
Osteoblasts were cultured to confluence in T-175 flasks containing 25 mL BME complete medium. Labeled (U-13C5, 15N) proline
(Cambridge Isotope Laboratories) and (U-13C2, 15N) glycine (Cambridge Isotope Laboratories) were added after filter sterilization
(0.22 mm filter) to a final concentration of 46 mg/L and 30 mg/L respectively and 1g/L of U-13C-glucose (Cambridge Isotope Labo-
ratories). The cultures were incubated at 37#C in a humidified atmosphere of 95% air and 5%CO2. The culture medium with isotope
labeled supplements was renewed every 2 days until the cells and matrix began to detach from the culture flask, by which time
enough ECM had formed for SSNMR. Samples from more than 20 batches using the final optimized protocol were prepared using
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isotope-enriched amino acids and similarly for samples incorporating U-13C-glucose and all characterized by SSNMR to ensure
reproducibility of results.
Recovery of ECM
The matrix was harvested after 9 days of culture, when the cells produce a dense matrix which started to peel off the surface of the
tissue culture flask. The medium was removed and the cells were washed with 20 mL 1 x phosphate buffered saline (1X PBS). The
flask was placed in a freezer at!80#C for 24 hours and the cells were lysed by thawing the flasks at room temperature for 30minutes.
The debris produced by cell lysis was removed by repeated washes with PBS. The decellularized ECM was dislodged by gently
swirling the flask in the presence of 20 mL PBS. The matrix collected in PBS was transferred to a fresh 50 mL tube and centrifuged
at 1200 rpm for 5 min at room temperature. The supernatant was poured off and the ECM dehydrated in an oven at 37#C overnight.
The samples were stored at !20#C until NMR analysis.
ECM of mouse tissue was used directly in SSNMR experiments without extraction, purification, or excessive processing where
possible. Tissues used in each experiment are described below in the SSNMR section.
Solid-state NMR spectroscopy of VSMC and fetal sheep osteoblast extracellular matrix
To prepare the matrix for DNP NMR, the bovine VSMC matrix sample was mixed with D2O/H2O (v/v = 3/1) and a final AMUPol
concentration of 10mM, and packed into 3.2 mm zirconia rotors with a Vespel drive cap. The 2D 13C-13C dipolar-assisted rotational
resonance (DARR) correlation spectrum was acquired on a Bruker Avance III NMR spectrometer with a 9.4 T superconducting mag-
net, equipped with a 3.2 mm triple resonance low temperature DNP-MAS probe and Larmor frequencies of 400 MHz 1H, 100 MHz
13C. The magnet was coupled with a first harmonic gyrotron giving constant microwave irradiation at 263.6 GHz. The sample was
cooled in the spectrometer to 100 K, and the NMR experiment conducted at the same temperature with 8889 Hz magic-angle
spinning (MAS), using n)1 = nR1H continuous wave irradiation (DARR) during the mixing period. Parameters used in the NMR
experiments were 2 s recycle delay, 4.3 ms 1H 90# pulse length, 1ms cross polarization contact time, 8.5 ms 13C 90# pulse length
and the DARR mixing time was 100 ms. 100 kHz SPINAL64 decoupling is applied during both incremental delay and acquisition.
Cross polarization used a ramped contact pulse on 13C. Chemical shifts are measured with respect to glycine Ca at 43.1 ppm, which
corresponds to the TMS 13C signal being at 0 ppm.
In vitro, cell-free nidus calcification models (Figures 4, 5, S4, and S5)
The in vitro calcification experiments with niduses of collagen fibrils, elastin, and DNA in the presence and absence of PAR were
carried out at RT in 1.5 mL Eppendorf tubes in a total volume of 100 ml.
Collagen (C-9879; from bovine Achilles tendon), elastin (E-1625; from bovine neck ligament) and DNA (D-1501; from calf thymus)
were purchased from Sigma-Aldrich as dry powders and stock solutions were prepared in DIW. Collagen purity was confirmed by
amino acid analysis and liquid chromatography (LC)/ mass spectroscopy (MS). Typical analysis:
Collagen stock solutions were sonicated on ice for at least 30 min prior to use.
Custom-made, EDTA-free PARwas purchased fromBioTechne/Trevigen and had a concentration of 100 mM (56 mg/ml; supplied in
10 mM TRIS buffer pH 8.0) and was stored in 50 mL aliquots under liquid nitrogen. Collagen (C-9879; from bovine Achilles tendon),
Asp 4.64
Thr 1.72
Ser 3.24
Glu 7.49
Gly 34.97
Ala 10.56
Val 2.39
Met 0.07
Ile 1.27
Leu 2.74
Tyr 0.44
Phe 1.45
His 0.51
Lys 2.43
Arg 5.08
Pro 11.42
HO-Pro 8.96
HO-Lys 0.63
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elastin (E-1625; frombovine neck ligament) andDNA (D-1501; fromcalf thymus) were purchased fromSigma-Aldrich as dry powders.
Collagen, elastin and DNA stock solutions were prepared at 1 mg/ml in DIW, PAR stock was used as provided and microvesicle (MV)
preparations (see below) were in 10 mM TRIS buffer pH 8. Collagen stock solutions were sonicated on ice for 30 min prior to use.
Separate Ca2+ (11.25 mM CaCl2 x 2 H2O) and PO4
3- (5.25 mM K2HPO4) stock solutions were prepared in 50 mM TBS (7.93 mM
TRIS-BASE, 41.9 mM TRIS-hydrochloride, 150 mM NaCl; pH 7.4).
Stock solutionswere filter sterilized if possible or contained 0.02%sodium azide in order to avoid bacterial growth. All plastic wares
were sterile, and samples were prepared under a sterile work bench. The various nidus additions (see below) were pipetted into
Eppendorf tubes in a total volume of 20 mL (negative control - no nidus addition, very little calcium phosphate precipitation even after
14 days; and positive control - addition of pre-formed calcium phosphate leading to extensive calcium phosphate precipitation after
1h - were included in every experiment). Then, 40 mL of Ca2+-stock solution was added, followed by 40 mL of PO4
3- - stock solution;
therefore, the Ca2+ and PO4
3- concentrations in the assay were 4.5 mM and 2.1 mM, respectively. The tubes were mixed and
incubated at RT for the times indicated. Then, samples were centrifuged at 8,000 g for 4 min in a swing-out rotor in a Heraeus table
centrifuge temperature-regulated to 20#C. 80 mL of supernatant was removed without disturbing the pellet and the sediments were
subsequently washed twice with 200 mL each of DIW (brought to a pH of "8 by the addition of dilute NaOH in order to avoid disso-
lution of any formed CaP). After the last centrifugation step, supernatants were removed asmuch as possible, leaving the sediment in
about 20 mL of DIW. Then, samples were re-suspended and applied to TEM sample grids and viewed by BF-TEMas described below.
The nidus additions (per 100 mL total sample volume) were as follows:
Dynamic light scattering
PAR (56 mg/ml PAR stock solution) wasmixed with an equal volume of ion solutions (i.e., 2mM stock solutions of CaCl2, MgCl2, ZnCl2
or MnCl2 in 10 mM TRIS pH 8 to give in-assay concentrations of 1 mM; or 9 mM CaCl2 to give an in-assay concentration of 4.5 mM
Ca2+) at RT for about 30 min prior to measurement. DNA was treated with chelex 100 resin for 1h at RT to remove any potential
divalent cations present in the commercial preparation and was then used as a control in the same manner (at 40 mg/ml in assay).
The hydrodynamic radii of PAR and DNA ± divalent cations were derived from their diffusion coefficients as measured by DLS in
optically transparent 96-well plates using a DynaPro Plate Reader (Wyatt Technology), and processed with the associated Dynamics
(version 7.1.9) software.
Bright-field transmission electron microscopy (BF-TEM)
For the visualization of PAR in the absence/presence of various divalent cations, PAR (56 mg/ml stock solution) was mixed in equal
volumes with 10 mM TRIS buffer pH 8 or with various ions (i.e., with 2 mM stock solutions of CaCl2, MgCl2, ZnCl2 or MnCl2 in 10 mM
TRIS pH 8 to give in-assay concentrations of 1 mM ions; or with 9 mM ion stock solution to give an in-assay concentration of 4.5 mM)
at RT for about 30 min. DNA was treated with chelex 100 resin for 1h at RT to remove any potential divalent cations present in the
commercial preparation prior to incubation with CaCl2 solutions. Then, 5 mL of solution was adsorbed onto glow-discharged 400
mesh copper/carbon-film grids (EM Resolutions) for about 2 min. Grids were rinsed on two drops of DIW and negative staining
was performed using a 2% aqueous uranyl acetate solution. Samples destined for energy-dispersive X-ray spectroscopy (EDX)
were left unstained.
For the co-incubation of PAR (±ions) with collagen, PAR was incubated first with TRIS buffer or with the indicated concentration of
Ca2+ or Mn2+ ions as described above. Subsequently, an equal volume of collagen suspension ("1mg/ml in DIW) was added and the
mixture was again incubated at RT for the indicated length of time. TEM sample grids were then prepared and left unstained (for EDX)
or stained with uranyl acetate as described above. The samples obtained in the in-vitro nidus experiments were left unstained and
were viewed by their inherent electron density alone. Five ml of nidus suspensions were applied to 400 mesh copper-holey carbon
film grids (EM Resolutions) and allowed to air dry prior to BF-TEM. Grids were viewed in an FEI Tecnai G2 electron microscope run at
200 kV using a 10 mm objective aperture to enhance contrast. Images were acquired using Deben software. The size of PAR-ion
droplets wasmeasured using ImageJ software and size-frequency distributions were prepared using Analyze-it software embedded
Sample Addition 1 Addition 2
negative control 20 ml DIW -
positive control 1 mg pre-formed CaP -
collagen 10 mg collagen -
elastin 10 mg -
DNA 10 mg DNA -
PAR 0.56 mg PAR (10 ml stock solution)
collagen + DNA 10 mg collagen 10 mg DNA
collagen + PAR 10 mg collagen 0.56 mg PAR
elastin + DNA 10 mg elastin 10 mg DNA
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in Excel. EDX (energy-dispersive X-ray spectroscopy) was performed on unstained samples using a Peltier-cooled EDAX Ametek
window-less octane silicone drift detector and EDAX Genesis software. SAED (selected-area electron diffraction) was performed
at 200 kV in diffraction mode at spot size 7 and a camera length of 0.52 m.
In order to assess whether there was preferential localization of PAR-Ca droplets to collagen fibril hole zones, PAR was incubated
with 0.5 mM Ca2+ for 30 min prior to the addition of collagen for another 30 min. This concentration of Ca2+ was chosen as previous
experiments had shown that the diameter of the resulting PAR-Ca droplets was about 26 nm, small enough to potentially bind to a
single collagen hole zone without overlap. Then, TEM grids were prepared and stained with uranyl acetate as described above.
Images of 27 individual collagen fibers incubated with PAR-Ca droplets were acquired.
For each fiber, the total number of bound PAR-Ca droplets was counted, aswell as the number of droplets bound to the hole zones.
In addition, the total length of the collagen fiber so assessed wasmeasured as well as the length of all the component, individual hole
zones. Then, the percentage of PAR-Ca droplets bound to the hole zonewas calculated for each image. In total, 992 PAR-Ca droplets
were counted over a total length of 39 mmof collagen fibers and the calculation of the cumulativemean gap zone (in%) stabilized after
assessing about 20 individual images, making the measurement statistically meaningful.
Elastin/nidus sample embedding for BF-TEM
All TEM processing steps before dehydration of the samples were carried out at pH 8 to ensure that any CaP mineral of the samples
would not be dissolved during the procedure. Sediment samples from the in vitro nidus model were mixed with an equal volume of
20% gelatine (Sigma G-2500; in 0.05 M sodium cacodylate buffer pH 8) warmed to about 50#C, quickly transferred onto glass slides
and allowed to set at 4#C. The set gelatin was cut into fine pieces using a razor blade and transferred into fixative (2%glutaraldehyde/
2% formaldehyde in NaCAC) and fixed overnight at 4#C. Fixative was removed by washing 5x in 0.05% sodium cacodylate buffer
pH 8 ( = ‘NaCAC’) and the samples were osmicated (1% osmium tetroxide/1.5% potassium ferrocyanide in NaCAC) for 3 days at
4#C. After several washes (NaCAC), samples were treated for 20 min at RT with 1% thiocarbohydrazide/DIW and then washed again
using NaCAC. Subsequently, samples were osmicated a second time for 1h (2% osmium tetroxide in NaCAC). Samples were then
washed 4x in DIW (brought to pH of about 8 by addition of dilute NaOH) before being dehydrated in 50/70/95/100% ethanol (at least
3x for 5 min in each). Then, samples were bulk stained overnight using 2% uranyl acetate/100% methanol. Samples were washed
several times in dried, 100% ethanol and then further dehydrated using dry acetone and dry acetonitrile (at least 3 exchanges in each
solvent). Samples were then incubated in 50% acetonitrile 50% Quetol 651 epoxy resin overnight. This operation was followed by
four daily changes of 100% resin. The resinmixture contained: 12 gQuetol 651 (Agar), 15.7 gNonenyl Succinic Anhydride (NSA) hard-
ener, 5.7 g methyl-5-norbornene-2,3-dicarboxylic anhydride (MNA) hardener and 0.5 g benzyldimethylamine (BDMA) catalyst. They
were then cured at 60#C for 48 h. Elastin - as supplied by Sigma - was embedded using the above method except that the bulk stain
was carried after the second osmication step using 2% uranyl acetate in 0.5 Mmaleate buffer pH 5.5 for 3 days at 4#C; instead of the
bulk stain in methanol as described above - and washing steps were performed using DIW).
Thin sections (60-90 nm) were cut using a Leica Ultracut UCT ultramicrotome and collected on bare 300 mesh copper grids and
were not post-stained. Grids were viewed using an FEI Tecnai G2 in bright fieldmode operated at 200 kV and using a 10 mmobjective
aperture to improve contrast.
Block-face SEM imaging of warfarin-induced vascular calcification in rats
Aorta were dissected after 7 days and fixed by immersion in 10% acrolein in anhydrous methanol for 12 hours. They were rinsed x10
in anhydrous methanol, and twice in acetonitrile before embedding in Quetol 651 as described above. Cross sections of embedded
aortae were glued to Leica cryo-pins with conducting epoxy resin. The aortae were sectioned with glass knives in a Huxley mark II
ultramicrotome until a complete transverse profile was revealed. The pins were removed and the blocks and pins were coated with
70 nm of gold in an Emitech sputter coater. They were returned to the ultramicrotome and a mirror surface was produced by
sectioning dry with a Dupont diamond knife. The blocks were then coatedwith 30nmof carbon in aQuorumK150 evaporative carbon
coater. They were viewed in an FEI Verios 460L SEM using all six segments of a concentric backscattered detector, operated in full
immersion mode, at an accelerating voltage of 20 kV and a probe current of 400 pA. EDX spectra were collected for 100 s live time
using a 60 mm2 Silicon Drift Detector in an EDAX spectrometer running Genesis software.
Effect of PARP inhibitors on in vitro human VSMC calcification (Figures 6 and S6)
RNA isolation, reverse transcription, and real-time PCR for hVSMCs
Cells were lysed in RNA STAT-60 (Amsbio) according to manufacturer’s protocol. NanoDrop ND-1000 spectrophotometer was then
used to measure the concentration of isolated RNA. Reverse transcription of RNA was carried out with Random primers (Promega),
Oligo dT primers (Promega), dNTP mix (Eurogentec), RNAsin RNase inhibitor (Promega), 5x Mu-MLV buffer (Eurogentec), Mu-MLV
reverse transcriptase (Eurogentec) andDEPCH2O. The RNA and primers were incubated at 65#C for 5minutes prior to the reaction to
denature the RNA. The reverse transcription reaction was carried out at 25#C for 10 minutes for primers to anneal and then 37#C for
50 minutes for the reverse transcription to produce cDNA. A final incubation at 95#C for 5 minutes terminated the reaction and inac-
tivated reverse transcriptase. The reaction was then cooled to 4#C in an Applied Biosystems 2720 Thermal Cycler. The resulting
cDNA was diluted to 2 mg/100 mL in DEPC H2O.
Real-time qRT-PCR was carried out in 20 mL reactions with 2 3 MESA GREEN qPCR MasterMix at a final concentration of
0.125 mMof each primer in a Corbette Rotor Gene 3000. 40 cycles of 95#C for 15 s and 60#C for 60 s were carried out, with melt curve
analysis step at the end. The expression of all genes was quantified using 2-DDCt Method, with GAPDH used as an internal control.
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The validated primers used for this method is as follows; PARP1: PP00686B (QIAGEN); PARP2: PPH02684F (QIAGEN); BMP2:
QT00012544 (QIAGEN); OCN: F:GGCAGCGAGGTAGTGAAGAG R: CGATAGGCCTCCTGAAAGC (Integrated DNA Technologies);
MSX2: F: AAATTCAGAAGATGGAGCGGCGTG R: CGGCTTCCGATTGGTCTTGTGTTT (Integrated DNA Technologies); SMA: F:TTG
AAGGCAAAGACATGGCAGCAG R:TCCACGGTAGTGCCCATCATTCTT (Integrated DNA Technologies); SM22: F:TTGAAGGCAA
AGACATGGCAGCAG R:TCCACGGTAGTGCCCATCATTCTT (Integrated DNA Technologies); GAPDH: F:CGACCACTTTGTCA
AGCTC R:CAAGGGGTCTACATGGCAAC (Integrated DNA Technologies).
RNA isolation, reverse transcription, and real-time PCR: MC3T3-E1 cultures
The cells were harvested at day 12 and total RNAs were isolated from cultures by RNeasy mini kit according to the manufacturer’s
instructions (QIAGEN) and quantified using NanoDrop (Thermo). First-strand cDNAwas synthesized from 1 mg of total RNA using RT2
First Strand Synthesis kit (QIAGEN). Typical reaction mix consists of SYBR green reaction master mix (12.5 ml), gene specific primer
(1 mM), diluted cDNA (15 ng) and nuclease-free water in a total reaction volume of 25 ml.
The temperature cycling conditions for RT PCR consists of an initial denaturation step at 95#C for 30 s followed by 40 cycles of
95#C, 10 s and 60#C, 30sec. RT-PCR was carried out using a Bio-Rad CFX96 Touch Real-Time PCR Detection System (Bio-Rad).
GAPDH was used as the reference gene. Samples were run in triplicate and data was analyzed using CFX Maestro Software
(Bio-Rad).
Validated gene (mouse) specific primer sets for use in SYBR Green-based real-time RT-PCR were procured from QIAGEN
(QuantiTect Primer Assay) and the primer code for the genes are as follows; Osterix (Osx): QT00293181 1Mm_Sp7_1_SGQuantiTect
Primer Assay; Type 1 collagen alpha chain: QT00162204 1Mm_Col1a1_1_SGQuantiTect Primer Assay; Osteopontin: QT00157724 1
Mm_Spp1_1_SG QuantiTect Primer Assay; Osteocalcin: QT00259406 1 Mm_Bglap_1_SG QuantiTect Primer Assay; Osteonectin:
QT00161721 1Mm_Sparc_1_SGQuantiTect Primer Assay; Alkaline phosphatase: QT00157717 1Mm_Alpl_1_SGQuantiTect Primer
Assay; GAPDH: QT01658692 1 Mm_Gapdh_3_SG QuantiTect Primer Assay; PARP1: QT00157584 1 Mm_Parp1_1_SG QuantiTect
Primer Assay and PARP2: QT00162281 1 Mm_Parp2_1_SG QuantiTect Primer Assay.
Alizarin red staining of calcification
The cells were washed twice with phosphate-buffered saline (PBS) and then fixed with 4% paraformaldehyde (PFA) for 10 minutes at
room temperature. Following this, the cells were washed twice with dH2O and stained with 2% Alizarin red for 5 minutes and rinsed
with water.
Cresolphthalein assay of calcification
Human VSMCs were plated with duplicates for each condition, so that one well would serve to provide protein lysates for normal-
ization. The cells were washed twice with Hank’s Balanced Salt Solution (HBSS, Trevigen), followed by overnight incubation at
4#C in 100 mL 0.1M HCl to dissolve the mineral deposits, or in 100 mL 0.1M NaOH/1% SDS to lyse the cells for protein normalization.
On the following day, 5 mL of each HCl decalcified sample were transferred to a 96-well plate andmixedwith 75 mL of dH2O before the
addition of 10 mL of o-cresolphthalein solution (5 mg o-cresolphthalein complexone in 3.6 mL dH2O + 1.4 mL ammonia buffer) and
200 mL ammonia buffer (5 mL ammonium hydroxide, 0.24 g ammonium chloride in 100 mL dH2O pH 10.5). Serial dilutions of CaCl2
weremade to form a standard curve and the absorbance wasmeasured at 540 nm using TECANGenios Promultifunctionmicroplate
reader. Calcium concentrations were calculated and normalized to protein concentrations determined using DC Protein Assay
(Bio-Rad) with absorbance measured at 710nm using Tecan Genios Pro multifunction microplate reader.
PARP activity assay in cells
The PARP activity of hVSMCs was tested with an HT colorimetric PARP/apoptosis assay kit (4684-096-K; Trevigen), according to the
manufacturer’s protocol. After calcification treatments of hVSMCs, the cells were lysed in cell extraction buffer prepared from the kit.
Equal amounts of protein extracts were then incubated with PARP substrate cocktail together with histone-coated strip wells. The
poly (ADP-ribose) on the strip wells was then detected by monoclonal anti-poly (ADP-ribose) antibody and HRP-conjugated goat
anti-mouse IgG antibody, with washing for each step. TACS-Sapphire colorimetric substrate from the kit was then added. Absor-
bance was read at 450 nm using BioTek ELx800 multifunction microplate reader.
Cell vitality assay
The cell vitality of hVSMC was measured by Solution 5 VB-48-PI-AO (910-3005; Chemometec) using the NucleoCounter! NC-3000
system, according to the manufacturer’s protocol. After calcification treatments of VSMCs, the cells were trypsinized and resus-
pended with the appropriate amount of medium. Following this step, cell sample were added into microcentrifuge tube (one volume
of solution 5 into 19 volumes of cell suspension). Thenmixed sample was added on a 2-chamber slide or an 8-chamber slide depend-
ing on the number of cells. Lastly, the assay was immediately performed using NucleoCounter! NC-3000.
PARP inhibitors
Inhibitor stock solutions were made in DMSO (Sigma) at 10 mM. For the inhibitor experiments, the VSMCs were treated with either
DMSO (vehicle), the PARP inhibitors PJ34 (AdipoGen), Minocycline (Cycle Pharm), Olaparib, Rucaparib, Niraparib, Veliparib (LGM
Pharma), or with the PARG inhibitor DEA (6,9-diamino-2-ethoxyacridine-DL-lactate) (Sigma) at indicated concentrations diluted in
the same medium used in the high Ca/P media, GAD-medium, control media or serum-free DMEM media.
PARP enzymatic activity assay with inhibitors
PARP activity and inhibition was measured for recombinant human full length active PARP1 and PARP2 enzymes (ab79663 and
ab198766 respectively, Abcam) according to the kit description (Merck Millipore, 10149) with some alterations. Inhibitor compounds
were added to the reaction buffer, prepared as a 1:1 mixture of Merck kit buffer with 50mM Tris-HCl, 100 mM NaCl, 5mM MgCl2,
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0.05% Tween-20, pH 8.0 (Sigma), and pre-incubated with PARP1 (2.5 ng/mL final) or PARP2 (12ng/mL final) at room temperature for
30 min. Further steps were performed following the kit instruction and fluorescence measurement of a product derived from nicotin-
amide (itself product of PARP reaction) was carried out at 420 nm excitation and 460 nm emission in FLUOstar Omega platereader
(BMG Labtech). Reaction sample without inhibitor was considered as 0%, and without NAD+ was considered as 100% inhibitory
value.
Rat CKD model
After isolation of the proximal part of the thoracic aorta, the tissue was fixed in neutral buffered formalin for 90 minutes and cut into
sections of 2-3mm. These 15-20 sections were embedded upright in a paraffin block and 4 mmsections were stained for calcification
with Von Kossa’s method and counterstained with hematoxylin and eosin.
The%of calcified areawas calculated using Axiovision image analysis software (Release 4.5, Carl Zeiss, Oberkochen, Germany) in
which two color separation thresholds measure the total tissue area and the Von Kossa positive area. After summing both absolute
areas, the% of calcified area was calculated as the ratio of the Von Kossa positive area versus the total tissue area. The proximal part
of the abdominal aorta and the left carotid and femoral artery were isolated and weighed on a precision balance. Subsequently, the
samples were digested in 65% HNO3 at 60#C for 6 hours. The calcium content of each artery was measured with FAAS and
expressed as mg calcium/g wet weight tissue.
The study of PAR, gH2AX and aSMA expression was performed using immunohistochemistry of these rat thoracic aortas. After
deparaffinization and rehydration, the sections were incubated in citric acid based antigen retrieval buffer for 25 min and then left
to cool down. These slides were then immerged in 3% H2O2 prepared in methanol to avoid any endogenous peroxidase activity.
After washing, the aortic sections were blocked in 10% blocking serum for 30min. The primary antibodies were diluted in blocking
serum and slides were left overnight at 4oC. Following washing, these sections were incubated with biotinylated secondary
antibodies diluted in blocking serum for 1h at RT. Subsequently, the slides were incubated with ABC reagent (kit) for 30 min. DAB
peroxidase substrate kit was used to develop the appropriate color and sections were counterstained with hematoxylin. The slides
were mounted using DPX following dehydration.
Images were taken using Leica ICC50 W microscope. The gH2AX expression was quantified using ImageJ software by counting
gH2AX positive (brown) and negative (purple) number of cells. After calculating the total number of cells, the % of gH2AX cells was
calculated as the ratio of gH2AX positive versus the total number of cells.
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM)
Rats femurs were removed after animals were sacrificed. After de-fleshing, the bones were preserved in 100% ethanol until further
analysis. In order to obtain cross-sections for SEM, the femurs were plunge-frozen and cleaved at liquid nitrogen temperatures at
both ends, where the long-bone section starts to transition into the joint area. Samples were freeze-dried in a liquid nitrogen-cooled
Quorum Emitech K775X turbo freeze-dryer and mounted on aluminum SEM stubs using double-sided sticky tape. Samples were
made conductive by painting with Ag-DAG electropaint and were coated with 35 nm gold/15 nm iridium prior to viewing in a FEI
Verios 460 SEM. SE imageswere taken at 2 keV accelerating voltage and 25mAprobe current using the EDT detector; high resolution
images were obtained using the TLD detector in full immersion mode. Large areamaps of the cross sections were obtained using the
FEI MAPS automated image acquisition software. ImageJ software was used to evaluate the extent of bone remodelling in the rat
femur samples (see image). First, the counting area of the cross-section was delineated bymarking the outside (green line) and inside
border (orange line) of the cortical bone area; then, a square lattice was superimposed and the number of grid intersections falling on
areas of solid bone (black dots) and areas of bone remodelling (purple dots) were counted. The area fraction of solid bone in the
cortical area was calculated as: Area fraction of solid bone (in %) = 100 * number of solid bone intersections/total number of area
intersections.
QUANTIFICATION AND STATISTICAL ANALYSIS
Results are presented as mean ± SEM unless stated otherwise. Statistical analysis was performed with GraphPad software. All the
data was tested for normalcy using the Shapiro-Wilk test. The comparisons were made using non-parametric Kruskal Wallis tests for
all studied groups; if the results were significant, each independent group was compared by Mann-Whitney U test. The parametric
t test was assessed in case of normal distribution between 2 independent groups or with 1-way ANOVA with Dunnett’s post hoc test.
For comparisons of multiple groups 2 say ANOVA with Turkey’s test was used.
Rat CKD model (Figures 7 and S7)
Results are expressed as mean ± SEM unless otherwise indicated. Non-parametric statistical analyses were performed with SPSS
24.0 software. As many study groups have been included in this study, multiple statistical tests have been performed.
(i) To determine differences at each time point and for each parameter between the rats with normal renal function (NRF + vehicle)
and the CKD groups, a Kruskal-Wallis (KW) test was assessed including all study groups. If the KW test showed significance, a
Mann-Witney U test was performed to compare differences between 2 independent groups; to this end, all CKD groups were
compared with the NRF + vehicle group in order to test whether differences between each CKD group and the control group
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(NRF + vehicle) were present. Bonferroni correction was applied to correct for multiple comparisons. A value of p < 0.05 was
considered significant.
(ii) To determine differences at each time point and for each parameter between the CKD groups treated with minocycline for
6 weeks versus the CKD group treated with vehicle for 6 weeks, a KW test was assessed including the CKD + vehicle 6
wks, CKD + MC/05 6 wks, CKD + MC/10 6 wks and CKD + MC/50 6 wks groups. If the KW test showed significance, a
Mann-Witney U test was performed to compare differences between 2 independent groups; to this end, all CKD + MC study
groups were compared with the CKD + vehicle group in order to test whether differences between each minocycline treated
CKD group and the vehicle treated CKD group were present. Bonferroni correction was applied to correct for multiple
comparisons. A value of p < 0.05 was considered significant.
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